<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction) - Alikhan, R - 2014 | Cochrane Library</title> <meta content="Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction) - Alikhan, R - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003747.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction) - Alikhan, R - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003747.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003747.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction)" name="citation_title"/> <meta content="Raza Alikhan" name="citation_author"/> <meta content="University Hospital of Wales" name="citation_author_institution"/> <meta content="raza@doctors.org.uk" name="citation_author_email"/> <meta content="Rachel Forster" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="Alexander T Cohen" name="citation_author"/> <meta content="Kings College Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD003747.pub4" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/05/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003747.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003747.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003747.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; Anticoagulants [*therapeutic use]; Heparin [*therapeutic use]; Heparin, Low‐Molecular‐Weight [therapeutic use]; Pulmonary Embolism [*prevention &amp; control]; Randomized Controlled Trials as Topic; Venous Thromboembolism [*prevention &amp; control]; Venous Thrombosis [prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003747.pub4&amp;doi=10.1002/14651858.CD003747.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ZDBB8PHY";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003747\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003747\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003747\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003747\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","zh_HANS","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003747.pub4",title:"Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction)",firstPublishedDate:"May 7, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003747.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003747.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003747.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003747.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003747.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003747.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003747.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003747.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003747.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003747.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6100 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003747.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/full#CD003747-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/full#CD003747-sec-0094"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/full#CD003747-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/full#CD003747-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/full#CD003747-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/full#CD003747-sec-0055"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/full#CD003747-sec-0088"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/appendices#CD003747-sec-0099"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/table_n/CD003747StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/table_n/CD003747StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction) </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/information#CD003747-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Raza Alikhan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/information#CD003747-cr-0003">Rachel Forster</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003747.pub4/information#CD003747-cr-0004">Alexander T Cohen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/information/en#CD003747-sec-0119">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 May 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003747.pub4">https://doi.org/10.1002/14651858.CD003747.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003747-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003747-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003747-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003747-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003747-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003747-abs-0001" lang="en"> <section id="CD003747-sec-0001"> <h3 class="title" id="CD003747-sec-0001">Background</h3> <p>Venous thromboembolic disease has been extensively studied in surgical patients. The benefit of thromboprophylaxis is now generally accepted, but it is medical patients who make up the greater proportion of the hospital population. Medical patients differ from surgical patients with regard to their health and the pathogenesis of thromboembolism and the impact that preventative measures can have. The extensive experience from thromboprophylaxis studies in surgical patients is therefore not necessarily applicable to non‐surgical patients. This is an update of a review first published in 2009. </p> </section> <section id="CD003747-sec-0002"> <h3 class="title" id="CD003747-sec-0002">Objectives</h3> <p>To determine the effectiveness and safety of heparin (unfractionated heparin or low molecular weight heparin) thromboprophylaxis in acutely ill medical patients admitted to hospital, excluding those admitted to hospital with an acute myocardial infarction or stroke (ischaemic or haemorrhagic) or those requiring admission to an intensive care unit (unless the study population can be clearly defined as acute medical and not post‐surgical). </p> </section> <section id="CD003747-sec-0003"> <h3 class="title" id="CD003747-sec-0003">Search methods</h3> <p>For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co‐ordinator searched the Specialised Register (last searched November 2013) and CENTRAL (2013, Issue 10). </p> </section> <section id="CD003747-sec-0004"> <h3 class="title" id="CD003747-sec-0004">Selection criteria</h3> <p>Randomised controlled trials comparing unfractionated heparin (UFH) or low molecular weight heparin (LMWH) with placebo or no treatment, or comparing UFH with LMWH. </p> </section> <section id="CD003747-sec-0005"> <h3 class="title" id="CD003747-sec-0005">Data collection and analysis</h3> <p>One review author identified possible trials and a second review author confirmed their eligibility for inclusion in the review. Two review authors extracted the data. Disagreements were resolved by discussion. We performed the meta‐analysis using a fixed‐effect model with the results expressed as odds ratios (ORs) with 95% confidence intervals (CIs). </p> </section> <section id="CD003747-sec-0006"> <h3 class="title" id="CD003747-sec-0006">Main results</h3> <p>Sixteen studies with a combined total of 34,369 participants with an acute medical illness were included in this review. We identified 10 studies comparing heparin with placebo or no treatment and six studies comparing LMWH to UFH. Just under half of the studies had an open‐label design, putting them at a risk of performance bias. Descriptions of random sequence generation and allocation concealment were missing in most of the studies. Heparin reduced the odds of deep vein thrombosis (DVT) (OR 0.41, 95% CI 0.25 to 0.67; P = 0.0004) . The estimated reductions in symptomatic non‐fatal pulmonary embolism (PE) (OR 0.46; 95% CI 0.20 to 1.07; P = 0.07), fatal PE (OR 0.71; 95% CI 0.43 to 1.15; P = 0.16) and in combined non‐fatal PE and fatal PE (OR 0.66, 95% CI 0.43 to 1.02; P = 0.06) associated with heparin were imprecise. Heparin resulted in an increase in major haemorrhage (OR 1.65, 95% CI 1.01 to 2.71; P = 0.05). There was no clear evidence that heparin had an effect on all‐cause mortality and thrombocytopaenia. Compared with UFH, LMWH reduced the risk of DVT (OR 0.77; 95% CI 0.62 to 0.96; P = 0.02) and major bleeding (OR 0.43; 95% CI 0.22 to 0.83; P = 0.01). There was no clear evidence that the effects of LMWH and UFH differed for the PE outcomes, all‐cause mortality and thrombocytopaenia. </p> </section> <section id="CD003747-sec-0007"> <h3 class="title" id="CD003747-sec-0007">Authors' conclusions</h3> <p>The data from this review describe a reduction in the risk of DVT in patients presenting with an acute medical illness who receive heparin thromboprophylaxis. This needs to be balanced against an increase in the risk of bleeding associated with thromboprophylaxis. The analysis favoured LMWH compared with UFH, with a reduced risk of both DVT and bleeding. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003747-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003747-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003747-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003747-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003747-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003747-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003747-abs-0003" lang="en"> <h3>Heparin to prevent deep vein thrombosis or pulmonary embolism in acutely ill medical patients (excluding those with stroke or myocardial infarction) </h3> <p>Blood clots may form in the veins of patients who are admitted to hospital suffering from an acute medical illness. These types of blood clots are referred to as deep vein thromboses (DVT) and they may break free from the blood vessel wall and travel to the lungs and cause death, at which point they are referred to as a pulmonary embolism (PE). These types of blood clots and their prevention have been thoroughly studied in surgical patients but not as much in non‐surgical, medical patients, who make up a greater proportion of hospital patients. Medical patients differ from surgical patients with regard to their health, the progression of clots and the impact that preventative measures can have. The extensive experience from clot prevention studies in surgical patients is therefore not necessarily applicable to non‐surgical patients. </p> <p>Heparin is a blood thinning drug, which has been shown to reduce the occurrence of blood clots in patients after they have had surgery. Heparin exists in two forms, the original unfractionated (UFH) form and a newer form called low molecular weight heparin (LMWH). The aim of the current review is to determine the effectiveness and safety of heparin (UFH or LMWH) to prevent DVTs and PEs in non‐surgical, medical patients admitted to hospital, excluding those admitted to hospital with a heart attack or stroke or those requiring admission to an intensive care unit. The outcomes investigated in this review were DVT, PE that did not cause death, PE that resulted in death, combined non‐fatal and fatal PE, all‐cause death, bleeding complications and thrombocytopaenia, which is a condition that can be caused by heparin and results in decreased platelets in the blood. </p> <p>This review of 16 trials in 34,369 non‐surgical patients who suffered an acute medical illness found that heparin reduced the number of patients suffering DVTs but also increased the risk of bleeding complications when compared to participants that received a placebo or no medication. We had some concerns over how reliable the results were from the unblinded studies, which made up just under half of the studies. Also, most of the studies were lacking explanations of how the allocation of the treatments was performed. The lower risk of PEs (when combining those that caused death and those that did not) with heparin could have been a chance effect. There was no clear evidence of a difference in the rate of death or thrombocytopaenia. The review also found that patients who were given LMWH developed fewer DVTs and fewer bleeding complications compared with those given UFH, leading to the conclusion that LMWH is more effective and carries a lower risk of adverse events in preventing blood clots than with UFH. There was no clear evidence of differences between LMWH and UFH for PE, death or thrombocytopaenia. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003747-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003747-sec-0094"></div> <h3 class="title" id="CD003747-sec-0095">Implications for practice</h3> <section id="CD003747-sec-0095"> <p>Evidence from this systematic review indicates that heparin (LMWH and UFH) thromboprophylaxis reduces the risk of DVT in patients with an acute medical illness (excluding stoke and myocardial infarction). The benefit of a reduction in venous thromboembolic events has to be balanced against a potential increase in the risk of bleeding. The risks of DVT and major bleeding are reduced with LMWH compared with UFH, indicating LMWH to be superior to UFH. </p> </section> <h3 class="title" id="CD003747-sec-0096">Implications for research</h3> <section id="CD003747-sec-0096"> <p>Medical patients in the trials included in this review received thromboprophylaxis for between six to 28 days; at present the optimum duration of prophylaxis is unknown but most guidelines recommend between six to 14 days following admission to hospital with an acute medical illness, or during the hospital stay or time of immobilisation (<a href="./references#CD003747-bbs2-0047" title="KahnSR , LimW , DunnAS , CushmanM , DentaliF , AklEA , et al. American College of Chest Physicians. Prevention of VTE in non surgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence‐based clinical practice guidelines. Chest2012;141(2 Suppl):e195S‐226S. ">Kahn 2012</a>). Autopsy studies have identified patients suffering a fatal PE up to six weeks after an acute medical illness (<a href="./references#CD003747-bbs2-0031" title="AlikhanR , PetersF , WilmottR , CohenA . Fatal pulmonary embolism in hospitalised patients: ‐ a necropsy review. Journal of Clinical Pathology2004;57(12):1254‐7. ">Alikhan 2004</a>). The recently published <a href="./references#CD003747-bbs2-0020" title="HullR , SchellongS , TapsonV , YusenR , MonrealM , SamamaMM , et al. Extended thromboprophylaxis with enoxaparin in acutely ill medical patients with prolonged periods of immobilisation: the EXCLAIM study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC397. HullR , TapsonVF , SchellongS , YusenRD , MonrealM , SamamaMM , et al. The EXCLAIM Study: Extended thromboprophylaxis with enoxaparin in acutely ill medical patients with restricted mobility. Blood2003;102(11 (Part 2)):1‐514. HullRD , SchellongS , TapsonV , YusenR , MonrealM , SamamaMM , et al. Extended thromboprophylaxis in acutely ill medical patients with prolonged immobilisation: The EXCLAIM study. Blood2002;100(11):Abstract 3988. HullRD , SchellongSM , TapsonVF , MonrealM , SamamaMM , NicolP , et al. EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended‐duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Annals of Internal Medicine2010;153(1):8‐18. HullRD , SchellongSM , TapsonVF , MonrealM , SamamaMM , TurpieAG , et al. Extended‐duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. Journal of Thrombosis and Thrombolysis2006;22(1):31‐8. HullRD , SchellongSM , TapsonVF , MonrealM , SamamaMM , TurpieAGG , et al. Extended‐duration venous thromboembolism (VTE) prophylaxis in acutely ill medical patients with recent reduced mobility: The EXCLAIM study. XXIst Congress of the International Society of Thrombosis and Haemostasis; 2007 Jul 6‐12; Geneva. 2007. SchellongSM , HullRD , TapsonVF , MonrealM , SamamaMM , TurpieAGG , et al. Extended‐duration enoxaparin for venous thromboembolism prophylaxis in acutely ill medical patients: an evaluation of the EXCLAIM study based on a recently recommended composite efficacy endpoint. Blood2007;110(11):554a. TapsonVF , HullRD , SchellongSM , MonrealM , SamamaMM , TurpieAGG , et al. Consistent venous thromboembolism risk reduction by extended‐ versus standard‐duration enoxaparin prophylaxis in subgroups of acutely ill medical patients in the EXCLAIM study. Blood2007;110(11):552a. YusenRD , HullRD , SchellongSM , TapsonVF , MonrealM , SamamaMM , et al. The effects of the degree of mobility reduction and prespecified risk factors on venous thromboembolism rates in acutely ill medical patients in the EXCLAIM study. Blood2007;110(11):551a. YusenRD , HullRD , SchellongSM , TapsonVF , MonrealM , SamamaMM , et al. The impact of age on the efficacy and safety of extended‐duration thromboprophylaxis in acutely ill medical patients with recent immobility: a sub‐group analysis from the EXCLAIM Study. ASH2009; Vol. 112, issue 11:167. ">EXCLAIM</a> trial showed that LMWH administered for up to 38 days reduced the rates of VTE following discharge from hospital when compared to placebo, but this was associated with an increased risk of bleeding. Similar findings were found in two recent studies of extended thromboprophylaxis in medical patients, the <a href="./references#CD003747-bbs2-0028" title="GoldhaberSZ , LeizoroviczA , KakkarAK , HaasSK , MerliG , KnabbRM , et al. ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. New England Journal of Medicine2011;365(23):2167‐77. ">ADOPT</a> trial showed a trend but no clear reduction in VTE and the <a href="./references#CD003747-bbs2-0049" title="CohenAT , SpiroTE , BullerHR , HaskellL , HuD , HullR , et al. for the MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. New England Journal of Medicine2013;368(6):513‐23. ">MAGELLAN</a> trial showed a significant reduction in VTE. Both studies showed increased bleeding with extended therapy (<a href="./references#CD003747-bbs2-0028" title="GoldhaberSZ , LeizoroviczA , KakkarAK , HaasSK , MerliG , KnabbRM , et al. ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. New England Journal of Medicine2011;365(23):2167‐77. ">ADOPT</a>; <a href="./references#CD003747-bbs2-0049" title="CohenAT , SpiroTE , BullerHR , HaskellL , HuD , HullR , et al. for the MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. New England Journal of Medicine2013;368(6):513‐23. ">MAGELLAN</a>). These findings show that there are still questions, and little consensus, regarding optimal thromboprophylaxis duration and that further research is warranted in this area in order to determine how best to prevent VTE. </p> <p>There are a number of emerging new oral direct anticoagulants which have been approved for use for thromboprophylaxis in elective orthopaedic hip and knee arthroplasty (<a href="./references#CD003747-bbs2-0029" title="AgenoW , SpyropoulosAC , TurpieAGG . Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. Thrombosis and Haemostasis2012;107(6):1027‐34. ">Ageno 2012</a>). However, studies in patients with an acute medical illness have found that the benefit of VTE reduction is outweighed by the increased risk of bleeding (<a href="./references#CD003747-bbs2-0028" title="GoldhaberSZ , LeizoroviczA , KakkarAK , HaasSK , MerliG , KnabbRM , et al. ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. New England Journal of Medicine2011;365(23):2167‐77. ">ADOPT</a>; <a href="./references#CD003747-bbs2-0049" title="CohenAT , SpiroTE , BullerHR , HaskellL , HuD , HullR , et al. for the MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. New England Journal of Medicine2013;368(6):513‐23. ">MAGELLAN</a>). Future thromboprophylaxis studies should look to individualise thromboprophylaxis, offering it to patients at high risk of VTE and low risk of bleeding. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003747-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003747-sec-0022"></div> <section id="CD003747-sec-0023"> <h3 class="title" id="CD003747-sec-0023">Description of the condition</h3> <p>Venous thromboembolism (VTE) is a major health problem, the significance and seriousness of which is often not fully appreciated. VTE is one of the most important preventable causes of morbidity and mortality in hospital patients, having an annual incidence of one per 1000 individuals (<a href="./references#CD003747-bbs2-0037" title="DahlbackB . Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood2008;112(1):19‐27. ">Dahlback 2008</a>). Most clinicians, whatever their specialty, will experience patients with this condition. </p> </section> <section id="CD003747-sec-0024"> <h3 class="title" id="CD003747-sec-0024">Description of the intervention</h3> <p>During the past 40 years numerous studies have shown that UFH and LMWH are effective and safe for the prevention of VTE in surgical patients (<a href="./references#CD003747-bbs2-0042" title="GeertsWH , BergqvistD , PineoGF , HeitJA , SamamaCM , LassenMR , et al. Prevention of venous thromboembolism. Chest2008;133(6 Suppl):381S‐453S. ">Geerts 2008</a>). This has led to the widespread use of these agents for thromboprophylaxis in surgical patients with a resultant reduction in the incidence of fatal PE (<a href="./references#CD003747-bbs2-0033" title="CohenAT , EdmondsonRA , PhillipsMJ , WardVP , KakkarVV . The changing pattern of venous thromboembolic disease. Haemostasis1996;26(2):65‐71. ">Cohen 1996</a>). During the same period of time, there have been fewer trials investigating the benefits and risks of thromboprophylaxis in medical patients. Most of these studies have concentrated on specific conditions such as myocardial infarction (MI) (<a href="./references#CD003747-bbs2-0036" title="CollinsR , MacMahonS , FlatherM , BaigentC , RemvigL , MortensenS , et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ1996;313(7058):652‐9. ">Collins 1996</a>) and ischaemic stroke (<a href="./references#CD003747-bbs2-0043" title="GubitzG , SandercockP , CounsellC . Anticoagulants for acute ischaemic stroke (Review). Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD000024.pub2] ">Gubitz 2004</a>). </p> </section> <section id="CD003747-sec-0025"> <h3 class="title" id="CD003747-sec-0025">How the intervention might work</h3> <p>Thrombosis results from a disturbance in the balance between pro‐thrombotic and antithrombotic forces that exist within the blood stream. The pro‐thrombotic forces include platelets and the formation of fibrin. There are two phases of normal haemostasis; the first phase is platelet activation and adhesion, and the forming of a 'platelet plug'. In parallel, the second phase results in the activation of a series of procoagulant clotting factors, which generate a burst of thrombin, formation of fibrin and stabilisation of the platelet plug, resulting in a thrombus. When this process becomes unregulated venous thrombosis may occur in any vein in the body, although it usually occurs in the deep veins of the lower limbs. People admitted to hospital with an acute medical illness appear to be particularly at risk of suffering from thrombosis of these lower limb deep veins. </p> <p>Heparin (UFH and LMWH) binds to a naturally occurring anticoagulant, antithrombin (AT), via a pentasaccharide sequence. The heparin‐AT complex inactivates thrombin (factor IIa) as well as coagulation factors Xa, IXa and XIa. As a direct result of inactivating or reducing the generation of thrombin, fibrin formation is inhibited, as is thrombin directed activation of coagulation factors V, VIII and XI. In addition, thrombin mediated platelet activation is attenuated (<a href="./references#CD003747-bbs2-0040" title="GarciaDA , BaglinTP , WeitzJI , SamamaMM , American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e24S‐e43S. ">Garcia 2012</a>). Therefore, heparin affects both the primary and secondary phases of thrombus formation and this is the rationale behind its use as a thromboprophylactic agent. </p> </section> <section id="CD003747-sec-0026"> <h3 class="title" id="CD003747-sec-0026">Why it is important to do this review</h3> <p>Unlike their surgical counterparts, it wasn't until the late 1990s and early part of the 21st century that physicians caring for general medical patients had convincing evidence of the efficacy and safety of thromboprophylaxis for their patients upon which to base prescribing decisions (<a href="./references#CD003747-bbs2-0042" title="GeertsWH , BergqvistD , PineoGF , HeitJA , SamamaCM , LassenMR , et al. Prevention of venous thromboembolism. Chest2008;133(6 Suppl):381S‐453S. ">Geerts 2008</a>). We believe that this has resulted in the underuse of thromboprophylaxis in the medical setting (<a href="./references#CD003747-bbs2-0030" title="AlikhanR , WilmottR , AgrawalS , DesouzaN , GeraA , ZawH , et al. Use of thromboprophylaxis in non‐surgical patients: survey of a London teaching hospital. Blood2001;98(11):271. ">Alikhan 2001</a>), and this continues to be a problem (<a href="./references#CD003747-bbs2-0034" title="CohenAT , TapsonVF , BergmannJF , GoldhaberSZ , KakkarAK , DeslandesB , et al. for the ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross‐sectional study. Lancet2008;371(9610):387‐94. ">Cohen 2008</a>). The under use may in part explain the high incidence rate of fatal PE in this patient group (<a href="./references#CD003747-bbs2-0031" title="AlikhanR , PetersF , WilmottR , CohenA . Fatal pulmonary embolism in hospitalised patients: ‐ a necropsy review. Journal of Clinical Pathology2004;57(12):1254‐7. ">Alikhan 2004</a>; <a href="./references#CD003747-bbs2-0053" title="SandlerDA , MartinJF . Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?. Journal of the Royal Society of Medicine1989;82(4):203‐5. ">Sandler 1989</a>). This is an update of a review first published in 2009 (<a href="./references#CD003747-bbs2-0056" title="AlikhanR , CohenAT . Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD003747.pub2] ">Alikhan 2009</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003747-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003747-sec-0027"></div> <p>The aim of this review is to determine the effectiveness and safety of heparin (unfractionated heparin (UFH) or low molecular weight heparin (LMWH)) thromboprophylaxis in acutely ill medical patients admitted to hospital, excluding those admitted to hospital with an acute myocardial infarction or stroke (ischaemic or haemorrhagic) or those requiring admission to an intensive care unit (unless the study population can be clearly defined as acute medical and not post‐surgical). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003747-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003747-sec-0028"></div> <section id="CD003747-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003747-sec-0030"> <h4 class="title">Types of studies</h4> <p> <ol id="CD003747-list-0001"> <li> <p>Randomised controlled trials comparing UFH with placebo or no treatment</p> </li> <li> <p>Randomised controlled trials comparing LMWH with placebo or no treatment</p> </li> <li> <p>Randomised controlled trials comparing UFH with LMWH</p> </li> </ol> </p> </section> <section id="CD003747-sec-0031"> <h4 class="title">Types of participants</h4> <p>People over the age of 18 years admitted to hospital with an acute medical illness, for example: </p> <p> <ul id="CD003747-list-0002"> <li> <p>heart failure;</p> </li> <li> <p>respiratory failure;</p> </li> <li> <p>cancer*;</p> </li> <li> <p>acute infection;</p> </li> <li> <p>episode of inflammatory bowel disease;</p> </li> <li> <p>acute rheumatic disorder.</p> </li> </ul> </p> <p>*Studies that primarily involve cancer patients not in an acute medical setting are excluded, such as receiving chemotherapy in tandem with thromboprophylaxis. This is the subject of another Cochrane review (<a href="./references#CD003747-bbs2-0039" title="DiNisioM , PorrecaE , FerranteN , OttenHM , CuccurulloF , RutjesAWS . Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD008500.pub2] ">Di Nisio 2012</a>). </p> <p>Studies involving participants with only myocardial infarction or stroke are excluded because the risk of VTE differs in this population, and therefore the need for thromboprophylaxis. <a href="./references#CD003747-bbs2-0036" title="CollinsR , MacMahonS , FlatherM , BaigentC , RemvigL , MortensenS , et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ1996;313(7058):652‐9. ">Collins 1996</a> and <a href="./references#CD003747-bbs2-0041" title="GeetsWH , HeitJA , ClagettGP , PineoGF , ColwellCW , AndersonFA , et al. Prevention of venous thromboembolism. Chest2001;119:132S. ">Geerts 2001</a> address these patient populations in reference to VTE and thromboprophylaxis. </p> <p>We included studies from intensive care units if they clearly defined their population as medical and not post‐surgical. Studies were excluded if they did not clearly define their intensive care unit population as suffering from acute medical illness. </p> </section> <section id="CD003747-sec-0032"> <h4 class="title">Types of interventions</h4> <p>Participants randomised to receive UFH, LMWH, placebo or no treatment. Fondaparinux and other pentasaccharide agents were excluded from this review as they are addressed in another Cochrane review that is currently in progress (<a href="./references#CD003747-bbs2-0054" title="SongY , LiuL , LiX , DingJ . Pentasaccharides for the prevention of venous thromboembolism. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD005134.pub2] ">Song 2011</a>). </p> </section> <section id="CD003747-sec-0033"> <h4 class="title">Types of outcome measures</h4> <section id="CD003747-sec-0034"> <h5 class="title">Primary outcomes</h5> <section id="CD003747-sec-0035"> <h6 class="title">Efficacy</h6> <p> <ul id="CD003747-list-0003"> <li> <p>Asymptomatic or symptomatic deep vein thrombosis (DVT) of the lower limbs detected by fibrinogen uptake test, ultrasound, venography or plethysmography </p> </li> <li> <p>Symptomatic non‐fatal PE detected by ventilation perfusion scan, computed tomography, pulmonary angiography, or confirmed at autopsy </p> </li> </ul> </p> </section> <section id="CD003747-sec-0036"> <h6 class="title">Safety</h6> <p> <ul id="CD003747-list-0004"> <li> <p>Major haemorrhage. As it was not possible to obtain a standardised definition of major bleeding, the study author's definition, where given, was used. See <a href="./references#CD003747-sec-0125" title="">Characteristics of included studies</a> for individual study definitions </p> </li> </ul> </p> </section> </section> <section id="CD003747-sec-0037"> <h5 class="title">Secondary outcomes</h5> <section id="CD003747-sec-0038"> <h6 class="title">Efficacy</h6> <p> <ul id="CD003747-list-0005"> <li> <p>All‐cause mortality</p> </li> <li> <p>Fatal PE</p> </li> <li> <p>Combined clinically symptomatic non‐fatal PE and fatal PE</p> </li> </ul> </p> </section> <section id="CD003747-sec-0039"> <h6 class="title">Safety</h6> <p> <ul id="CD003747-list-0006"> <li> <p>Minor haemorrhage. As it was not possible to obtain a standardised definition of minor bleeding, the study author's definition, where given, was used. See <a href="./references#CD003747-sec-0125" title="">Characteristics of included studies</a> for individual study definitions </p> </li> <li> <p>Thrombocytopaenia, as defined by individual study authors</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD003747-sec-0040"> <h3 class="title">Search methods for identification of studies</h3> <p>There was no restriction on the language of publication.</p> <section id="CD003747-sec-0041"> <h4 class="title">Electronic searches</h4> <p>For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co‐ordinator (TSC) searched the Specialised Register (last searched November 2013) and the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 10), part of <i>The Cochrane Library</i> (<a href="http://www.thecochranelibrary.com" target="_blank">www.thecochranelibrary.com</a>). See <a href="./appendices#CD003747-sec-0100">Appendix 1</a> for details of the search strategy used to search CENTRAL. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL and AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used are described in the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html" target="_blank">Specialised Register</a> section of the Cochrane Peripheral Vascular Diseases Group module in <i>The Cochrane Library</i> (<a href="http://www.thecochranelibrary.com" target="_blank">www.thecochranelibrary.com</a>). </p> </section> <section id="CD003747-sec-0042"> <h4 class="title">Searching other resources</h4> <p>In the previous version of this review we consulted with colleagues and investigators as well as the manufacturers of the various LMWH preparations to identify unpublished or missed studies. This was not done for the current version. </p> </section> </section> <section id="CD003747-sec-0043"> <h3 class="title" id="CD003747-sec-0043">Data collection and analysis</h3> <section id="CD003747-sec-0044"> <h4 class="title">Selection of studies</h4> <p>For this update one review author (RA) identified possible trials, and the trial reports were assessed independently by another review author (RB) to confirm eligibility for inclusion in the review. In the previous version of this review study selection was performed by RA and AC. </p> </section> <section id="CD003747-sec-0045"> <h4 class="title">Data extraction and management</h4> <p>For this update, RA and RB individually extracted the data using the following endpoints: DVT of the lower limbs; symptomatic non‐fatal PE; fatal PE; combined symptomatic non‐fatal and fatal PE; all‐cause mortality; major and minor bleeding (as defined by individual authors); and thrombocytopaenia (reduced numbers of platelets). We recorded all information collected on data extraction forms. We resolved disagreements by discussion. In the previous version of this review data extraction was performed by RA and AC. </p> </section> <section id="CD003747-sec-0046"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The methodological quality of included trials was assessed independently by RA and RB using the 'Risk of bias' tool from The Cochrane Collaboration (<a href="./references#CD003747-bbs2-0046" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). The following domains were assessed: selection bias (random sequence generation, allocation concealment), performance bias (blinding of participants and personnel, and blinding of outcome assessment), attrition bias (incomplete outcome data), reporting bias (selective reporting), and other bias. The domains were classified as low risk of bias, high risk of bias, or unclear risk of bias according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003747-bbs2-0046" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Disagreements were resolved by discussion between the two review authors assessing bias. </p> </section> <section id="CD003747-sec-0047"> <h4 class="title">Measures of treatment effect</h4> <p>We performed statistical analyses according to the statistical guidelines for authors recommended by the Cochrane Peripheral Vascular Diseases Group. </p> <p>We divided the studies into two groups and analysed them separately:</p> <p> <ol id="CD003747-list-0007"> <li> <p>heparin (UFH or LMWH) prophylaxis versus placebo or no treatment;</p> </li> <li> <p>LMWH versus UFH.</p> </li> </ol> </p> <p>For each of the two groups we pooled data from each study on DVT, non‐fatal PE, fatal PE, combined non‐fatal and fatal PE, all‐cause mortality, major bleeding, minor bleeding, and thrombocytopaenia in order to arrive at an overall estimate of efficacy and safety of heparin versus no treatment or placebo and LMWH versus UFH. We summarised the results of each trial on an intention‐to‐treat basis in 2 x 2 tables for each outcome measurement. Where possible, all randomised participants were included, even if the original trial authors excluded them. The results obtained from different methods were similar (risk ratios, Mantel‐Haenzel and Peto odds ratios), therefore the meta‐analysis was performed using odds ratios (ORs) with 95% confidence intervals (CIs). </p> </section> <section id="CD003747-sec-0048"> <h4 class="title">Unit of analysis issues</h4> <p>The individual participant was the unit of analysis in all included studies.</p> </section> <section id="CD003747-sec-0049"> <h4 class="title">Dealing with missing data</h4> <p>Analysis was performed on an intention‐to‐treat basis, including all participants randomised. </p> </section> <section id="CD003747-sec-0050"> <h4 class="title">Assessment of heterogeneity</h4> <p>A test for heterogeneity examines the null hypothesis that all studies are evaluating the same effect. We obtained P values comparing the test statistic with a Chi<sup>2</sup> distribution. To help readers assess the consistency of results of studies in a meta‐analysis, RevMan 5 software includes a method (I<sup>2</sup> statistic) that describes the percentage of total variation across studies due to heterogeneity rather than by chance. A value of 0% indicates no observed heterogeneity, and larger values show increasing heterogeneity (<a href="./references#CD003747-bbs2-0045" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). </p> </section> <section id="CD003747-sec-0051"> <h4 class="title">Assessment of reporting biases</h4> <p>To detect reporting bias we planned to construct funnel plots for meta‐analyses that included at least 10 studies, as funnel plots with less than 10 studies lack the power to distinguish chance from real asymmetry. </p> </section> <section id="CD003747-sec-0052"> <h4 class="title">Data synthesis</h4> <p>An heterogeneity test was performed and we planned to use a random‐effects model if the test was positive (I<sup>2</sup> &gt; 50%); unless otherwise stated the meta‐analysis was performed using a fixed‐effect model. </p> </section> <section id="CD003747-sec-0053"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where data were available, subgroup analysis was performed to evaluate outcomes based on medical diagnosis at hospital admission. </p> </section> <section id="CD003747-sec-0054"> <h4 class="title">Sensitivity analysis</h4> <p>Four studies included in the review had a loss of ≥ 20% of the study population between randomisation and evaluation for DVT or PE (<a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a>; <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>; <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>). Although the majority of the missing participants were accounted for with suitable reasoning, it was still possible these losses could alter the outcome. Sensitivity analysis was performed by removing these studies from the DVT and PE outcomes and evaluating their affect on the meta‐analysis. </p> <p>DVT diagnosis using a fibrinogen uptake test and plethysmography is often less accurate than by ultrasound or venography. In order to establish that the meta‐analysis results were not dependent on studies using these low‐accuracy tests, sensitivity analysis was conducted by removing three studies using a fibrinogen uptake test or plethysmography to detect DVT (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>) and the effect evaluated. </p> <p>The safety data for the <a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a> study was collected after a three month follow‐up period, which was different to the other studies that collected the efficacy and safety data during the same study time period. With this additional time allotted for these endpoints it was possible this study unduly altered the meta‐analysis, therefore sensitivity analysis was performed by removing this study from the meta‐analyses for major and minor bleeding, as well as thrombocytopaenia, and evaluating the effect. </p> <p>In two studies (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>) major bleeding was not defined, and was only described as 'major bleeding'. In order to determine if these studies with inadequate definitions of major bleeding were not having an overt effect on the meta‐analysis they were removed in a sensitivity analysis to evaluate the effect. </p> <p>Two studies (<a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>) included a low‐dosage (20 mg) of the LMWH enoxaparin. For <a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a> this was the only LMWH dosage, but for <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a> there was also a higher dosage of 40 mg. Sensitivity analysis was performed by removing the 20 mg dosages and the effect was evaluated. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003747-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003747-sec-0055"></div> <section id="CD003747-sec-0056"> <h3 class="title">Description of studies</h3> <section id="CD003747-sec-0057"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD003747-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD003747-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003747-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD003747-sec-0058"> <h4 class="title">Included studies</h4> <p>For this update there were an additional three studies included (<a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a>; <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>; <a href="./references#CD003747-bbs2-0012" title="Anon . Study to evaluate the mortality reduction of enoxaparin in hospitalized acutely ill medical receiving enoxaparin (LIFENOX). ClinicalTrials.gov NCT006226482010. KakkarAK , CimminielloC , GoldhaberSZ , ParakhR , WangC , BergmanJ‐F , for the LIFENOX Investigators. Low molecular weight heparin and mortality in acutely ill medical patients. New England Journal of Medicine2011;365(26):2463‐72. ">LIFENOX 2011</a>). For details of the included studies see <a href="./references#CD003747-sec-0125" title="">Characteristics of included studies</a>. </p> <p>We included 16 studies (45 published articles) with 34,369 participants. Ten of these studies compared heparin prophylaxis with no treatment or placebo (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0002" title="BergmannJF , CaulinC . Heparin prophylaxis in bedridden patients. Lancet1996;348(9021):205‐6. MaheI , BergmannJF , d'AzemarP , VaissieJJ , CaulinC . Lack of effect of a low‐molecular‐weight heparin (nadroparin) on mortality in bedridden medical in‐patients: a prospective randomised double‐blind study. European Journal of Clinical Pharmacology2005;61(5‐6):347‐51. ">Bergmann 1996</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>; <a href="./references#CD003747-bbs2-0009" title="GallusAS , HirshJ , TuttleRJ , TreblicockR , O'BrienSE , CarrollJJ , et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. New England Journal of Medicine1973;288(11):545‐51. ">Gallus 1973</a>; <a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>; <a href="./references#CD003747-bbs2-0011" title="Ibarra‐PerezC , Lau‐CortesE , Colmenero‐ZubiateS , Arévila‐CeballosN , FongJH , Sánchez‐MartínezR , et al. Prevalence and prevention of deep vein thrombosis of the lower extremities in high risk pulmonary patients. Angiology1988;39(6):505‐13. ">Ibarra‐Perez 1988</a>; <a href="./references#CD003747-bbs2-0012" title="Anon . Study to evaluate the mortality reduction of enoxaparin in hospitalized acutely ill medical receiving enoxaparin (LIFENOX). ClinicalTrials.gov NCT006226482010. KakkarAK , CimminielloC , GoldhaberSZ , ParakhR , WangC , BergmanJ‐F , for the LIFENOX Investigators. Low molecular weight heparin and mortality in acutely ill medical patients. New England Journal of Medicine2011;365(26):2463‐72. ">LIFENOX 2011</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>; <a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>) and six studies compared LMWH with UFH (<a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a>; <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>; <a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>; <a href="./references#CD003747-bbs2-0007" title="ForetteB , WolmarkY . Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Presse Medicale1995;24(12):567‐71. ">Forette 1995</a>; <a href="./references#CD003747-bbs2-0015" title="KellerF , FlosbachCW , THE PRIME ‐ Study Group. A randomised multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Thrombosis and Haemostasis1995;73(6):1106‐Abstract No 788. LechlerE , SchrammW , FlosbachCW . A randomized, multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised patients. Annals of Hematology1994;68 Suppl 1:A55. LechlerE , SchrammW , FlosbachCW , The PRIME Study Group. The venous thrombotic risk in nonsurgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis1996;26 Suppl 2:49‐56. ">PRIME 1996</a>; <a href="./references#CD003747-bbs2-0016" title="KleberFX , WittC , VogelG , KoppenhagenK , SchomakerU , FlosbachCW , THE‐PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal2003;145(4):614‐21. ">THE‐PRINCE 2003</a>). Fifteen of the included studies were written in English, and one in French (<a href="./references#CD003747-bbs2-0007" title="ForetteB , WolmarkY . Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Presse Medicale1995;24(12):567‐71. ">Forette 1995</a>) that we had translated. </p> <p>Four trials took place in a single centre (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0009" title="GallusAS , HirshJ , TuttleRJ , TreblicockR , O'BrienSE , CarrollJJ , et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. New England Journal of Medicine1973;288(11):545‐51. ">Gallus 1973</a>; <a href="./references#CD003747-bbs2-0011" title="Ibarra‐PerezC , Lau‐CortesE , Colmenero‐ZubiateS , Arévila‐CeballosN , FongJH , Sánchez‐MartínezR , et al. Prevalence and prevention of deep vein thrombosis of the lower extremities in high risk pulmonary patients. Angiology1988;39(6):505‐13. ">Ibarra‐Perez 1988</a>). Nine trials were European multi‐centre trials: four in France (<a href="./references#CD003747-bbs2-0002" title="BergmannJF , CaulinC . Heparin prophylaxis in bedridden patients. Lancet1996;348(9021):205‐6. MaheI , BergmannJF , d'AzemarP , VaissieJJ , CaulinC . Lack of effect of a low‐molecular‐weight heparin (nadroparin) on mortality in bedridden medical in‐patients: a prospective randomised double‐blind study. European Journal of Clinical Pharmacology2005;61(5‐6):347‐51. ">Bergmann 1996</a>; <a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>; <a href="./references#CD003747-bbs2-0007" title="ForetteB , WolmarkY . Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Presse Medicale1995;24(12):567‐71. ">Forette 1995</a>; <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>), one in Sweden (<a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>), three in Germany (<a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a>; <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>; <a href="./references#CD003747-bbs2-0016" title="KleberFX , WittC , VogelG , KoppenhagenK , SchomakerU , FlosbachCW , THE‐PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal2003;145(4):614‐21. ">THE‐PRINCE 2003</a>), and one in Germany and Austria (<a href="./references#CD003747-bbs2-0015" title="KellerF , FlosbachCW , THE PRIME ‐ Study Group. A randomised multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Thrombosis and Haemostasis1995;73(6):1106‐Abstract No 788. LechlerE , SchrammW , FlosbachCW . A randomized, multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised patients. Annals of Hematology1994;68 Suppl 1:A55. LechlerE , SchrammW , FlosbachCW , The PRIME Study Group. The venous thrombotic risk in nonsurgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis1996;26 Suppl 2:49‐56. ">PRIME 1996</a>). One trial was performed in multiple centres across Europe and Canada (<a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>) and two trials were truly multi‐national, one performed in centres across Europe, North and South America, Canada, North and Southern Africa, Israel, Lebanon and Australia (<a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>) and the other in China, India, Korea, Malaysia, Mexico, Philippines and Tunisia (<a href="./references#CD003747-bbs2-0012" title="Anon . Study to evaluate the mortality reduction of enoxaparin in hospitalized acutely ill medical receiving enoxaparin (LIFENOX). ClinicalTrials.gov NCT006226482010. KakkarAK , CimminielloC , GoldhaberSZ , ParakhR , WangC , BergmanJ‐F , for the LIFENOX Investigators. Low molecular weight heparin and mortality in acutely ill medical patients. New England Journal of Medicine2011;365(26):2463‐72. ">LIFENOX 2011</a>). </p> <section id="CD003747-sec-0059"> <h5 class="title">Heparin versus placebo or no treatment</h5> <p>Four trials compared UFH with no treatment (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0009" title="GallusAS , HirshJ , TuttleRJ , TreblicockR , O'BrienSE , CarrollJJ , et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. New England Journal of Medicine1973;288(11):545‐51. ">Gallus 1973</a>; <a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>; <a href="./references#CD003747-bbs2-0011" title="Ibarra‐PerezC , Lau‐CortesE , Colmenero‐ZubiateS , Arévila‐CeballosN , FongJH , Sánchez‐MartínezR , et al. Prevalence and prevention of deep vein thrombosis of the lower extremities in high risk pulmonary patients. Angiology1988;39(6):505‐13. ">Ibarra‐Perez 1988</a>). One study compared UFH 5000 IU twice daily (<a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>) and the other two studies compared UFH 5000 IU three times daily with no treatment (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0009" title="GallusAS , HirshJ , TuttleRJ , TreblicockR , O'BrienSE , CarrollJJ , et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. New England Journal of Medicine1973;288(11):545‐51. ">Gallus 1973</a>). </p> <p>Six trials compared LMWH with placebo, three trials were with enoxaparin (<a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0012" title="Anon . Study to evaluate the mortality reduction of enoxaparin in hospitalized acutely ill medical receiving enoxaparin (LIFENOX). ClinicalTrials.gov NCT006226482010. KakkarAK , CimminielloC , GoldhaberSZ , ParakhR , WangC , BergmanJ‐F , for the LIFENOX Investigators. Low molecular weight heparin and mortality in acutely ill medical patients. New England Journal of Medicine2011;365(26):2463‐72. ">LIFENOX 2011</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>), two trials with nadroparin (<a href="./references#CD003747-bbs2-0002" title="BergmannJF , CaulinC . Heparin prophylaxis in bedridden patients. Lancet1996;348(9021):205‐6. MaheI , BergmannJF , d'AzemarP , VaissieJJ , CaulinC . Lack of effect of a low‐molecular‐weight heparin (nadroparin) on mortality in bedridden medical in‐patients: a prospective randomised double‐blind study. European Journal of Clinical Pharmacology2005;61(5‐6):347‐51. ">Bergmann 1996</a>; <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>), and one trial with dalteparin (<a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>). One of the enoxaparin trials (<a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>) compared two doses (20 mg and 40 mg) of enoxaparin with placebo. For assessment of major and minor bleeding the maximum licensed duration of treatment was used. </p> </section> <section id="CD003747-sec-0060"> <h5 class="title">LMWH versus UFH</h5> <p>Six trials compared LMWH with UFH (<a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a>; <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>; <a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>; <a href="./references#CD003747-bbs2-0007" title="ForetteB , WolmarkY . Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Presse Medicale1995;24(12):567‐71. ">Forette 1995</a>; <a href="./references#CD003747-bbs2-0015" title="KellerF , FlosbachCW , THE PRIME ‐ Study Group. A randomised multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Thrombosis and Haemostasis1995;73(6):1106‐Abstract No 788. LechlerE , SchrammW , FlosbachCW . A randomized, multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised patients. Annals of Hematology1994;68 Suppl 1:A55. LechlerE , SchrammW , FlosbachCW , The PRIME Study Group. The venous thrombotic risk in nonsurgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis1996;26 Suppl 2:49‐56. ">PRIME 1996</a>; <a href="./references#CD003747-bbs2-0016" title="KleberFX , WittC , VogelG , KoppenhagenK , SchomakerU , FlosbachCW , THE‐PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal2003;145(4):614‐21. ">THE‐PRINCE 2003</a>). Three of these trials compared enoxaparin with UFH (<a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>; <a href="./references#CD003747-bbs2-0015" title="KellerF , FlosbachCW , THE PRIME ‐ Study Group. A randomised multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Thrombosis and Haemostasis1995;73(6):1106‐Abstract No 788. LechlerE , SchrammW , FlosbachCW . A randomized, multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised patients. Annals of Hematology1994;68 Suppl 1:A55. LechlerE , SchrammW , FlosbachCW , The PRIME Study Group. The venous thrombotic risk in nonsurgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis1996;26 Suppl 2:49‐56. ">PRIME 1996</a>; <a href="./references#CD003747-bbs2-0016" title="KleberFX , WittC , VogelG , KoppenhagenK , SchomakerU , FlosbachCW , THE‐PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal2003;145(4):614‐21. ">THE‐PRINCE 2003</a>). Two trials compared enoxaparin 40 mg once daily with UFH 5000 IU three times daily (<a href="./references#CD003747-bbs2-0015" title="KellerF , FlosbachCW , THE PRIME ‐ Study Group. A randomised multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Thrombosis and Haemostasis1995;73(6):1106‐Abstract No 788. LechlerE , SchrammW , FlosbachCW . A randomized, multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised patients. Annals of Hematology1994;68 Suppl 1:A55. LechlerE , SchrammW , FlosbachCW , The PRIME Study Group. The venous thrombotic risk in nonsurgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis1996;26 Suppl 2:49‐56. ">PRIME 1996</a>; <a href="./references#CD003747-bbs2-0016" title="KleberFX , WittC , VogelG , KoppenhagenK , SchomakerU , FlosbachCW , THE‐PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal2003;145(4):614‐21. ">THE‐PRINCE 2003</a>); one trial compared enoxaparin 20 mg once daily with UFH 5000 IU twice daily (<a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>). One trial compared nadroparin 3075 antiXa units once daily with UFH 5000 to 7500 IU three times daily (<a href="./references#CD003747-bbs2-0007" title="ForetteB , WolmarkY . Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Presse Medicale1995;24(12):567‐71. ">Forette 1995</a>). One trial compared certoparin 3000 antiXa units with UFH 5000 IU three times daily (<a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>). </p> </section> </section> <section id="CD003747-sec-0061"> <h4 class="title">Excluded studies</h4> <p>For this update one additional study was excluded (<a href="./references#CD003747-bbs2-0020" title="HullR , SchellongS , TapsonV , YusenR , MonrealM , SamamaMM , et al. Extended thromboprophylaxis with enoxaparin in acutely ill medical patients with prolonged periods of immobilisation: the EXCLAIM study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC397. HullR , TapsonVF , SchellongS , YusenRD , MonrealM , SamamaMM , et al. The EXCLAIM Study: Extended thromboprophylaxis with enoxaparin in acutely ill medical patients with restricted mobility. Blood2003;102(11 (Part 2)):1‐514. HullRD , SchellongS , TapsonV , YusenR , MonrealM , SamamaMM , et al. Extended thromboprophylaxis in acutely ill medical patients with prolonged immobilisation: The EXCLAIM study. Blood2002;100(11):Abstract 3988. HullRD , SchellongSM , TapsonVF , MonrealM , SamamaMM , NicolP , et al. EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended‐duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Annals of Internal Medicine2010;153(1):8‐18. HullRD , SchellongSM , TapsonVF , MonrealM , SamamaMM , TurpieAG , et al. Extended‐duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. Journal of Thrombosis and Thrombolysis2006;22(1):31‐8. HullRD , SchellongSM , TapsonVF , MonrealM , SamamaMM , TurpieAGG , et al. Extended‐duration venous thromboembolism (VTE) prophylaxis in acutely ill medical patients with recent reduced mobility: The EXCLAIM study. XXIst Congress of the International Society of Thrombosis and Haemostasis; 2007 Jul 6‐12; Geneva. 2007. SchellongSM , HullRD , TapsonVF , MonrealM , SamamaMM , TurpieAGG , et al. Extended‐duration enoxaparin for venous thromboembolism prophylaxis in acutely ill medical patients: an evaluation of the EXCLAIM study based on a recently recommended composite efficacy endpoint. Blood2007;110(11):554a. TapsonVF , HullRD , SchellongSM , MonrealM , SamamaMM , TurpieAGG , et al. Consistent venous thromboembolism risk reduction by extended‐ versus standard‐duration enoxaparin prophylaxis in subgroups of acutely ill medical patients in the EXCLAIM study. Blood2007;110(11):552a. YusenRD , HullRD , SchellongSM , TapsonVF , MonrealM , SamamaMM , et al. The effects of the degree of mobility reduction and prespecified risk factors on venous thromboembolism rates in acutely ill medical patients in the EXCLAIM study. Blood2007;110(11):551a. YusenRD , HullRD , SchellongSM , TapsonVF , MonrealM , SamamaMM , et al. The impact of age on the efficacy and safety of extended‐duration thromboprophylaxis in acutely ill medical patients with recent immobility: a sub‐group analysis from the EXCLAIM Study. ASH2009; Vol. 112, issue 11:167. ">EXCLAIM</a>) and there were 10 (<a href="./references#CD003747-bbs2-0017" title="AquinoJP , GambierA , DucrosJ . Prevention of thromboembolic accidents in elderly subjects with fraxiparine. In: BounameauxH , SamamaMM , TenCateJW editor(s). Fraxiparine, Second International Symposium Recent Pharmacological and Clinical Data. New York: Schattauer, 1990:51‐4. ">Aquino 1990</a>; <a href="./references#CD003747-bbs2-0018" title="CadeJF . High risk of the critically ill for venous thromboembolism. Critical Care Medicine1982;10(7):448‐50. ">Cade 1982a</a>; <a href="./references#CD003747-bbs2-0019" title="CadeJF , AndrewsJT , StubbsAE . Comparison of sodium and calcium heparin in prevention of venous thromboembolism. Australian and New Zealand Journal of Medicine1982;12(5):501‐4. ">Cade 1982b</a>; <a href="./references#CD003747-bbs2-0021" title="HalkinH , GoldbergJ , ModanM , ModanB . Reduction of mortality in general medical in‐patients by low dose heparin prophylaxis. Annals of Internal Medicine1982;96(5):561‐5. ">Halkin 1982</a>; <a href="./references#CD003747-bbs2-0022" title="HarenbergJ , KallenbachB , MartinU , DempfleCE , ZimmermannR , KublerW , et al. Randomised controlled study of heparin and low molecular weight heparin for prevention of deep vein thrombosis in medical patients. Thrombosis Research1990;59(3):639‐50. ">Harenberg 1990</a>; <a href="./references#CD003747-bbs2-0023" title="HarenbergJ , RoebruckP , HeeneDL , HESIM Group. Prevention of thromboembolism in medical inpatients. Haemostasis1994;24 Suppl 1:36‐Abstract No 36. HarenbergJ , RoebruckP , StehleG , HabscheidW , BiegholdtM , HeeneDL . Heparin Study in Internal Medicine (HESIM): design and preliminary results. Thrombosis Research1992;68(1):33‐43. HarenburgJ , RoebruckP , HeeneDL . Subcutaneous low molecular weight heparin versus standard heparin and the prevention of thromboembolism in medical patients. The Heparin Study in Internal Medicine (HESIM). Haemostasis1996;26(3):127‐39. ">HESIM</a>; <a href="./references#CD003747-bbs2-0024" title="MancietG , VergnesC , VaissieJJ , BoisseauMR . A study of the efficacy and tolerance of fraxiparine during long term therapy of the elderly. A randomized double‐blind clinical trial. In: BounameauxH , SamamaMM , TenCateJW editor(s). Fraxiparine Second International Symposium. Recent Pharmacological and Clinical Data. New York: Schattauer, 1990:55‐9. ">Manciet 1990</a>; <a href="./references#CD003747-bbs2-0025" title="MottierD . Prophylaxis of deep vein thrombosis in medical geriatric patients. Thrombosis and Haemostasis1993;69(6):1115‐Abstract No. 2045. ">Mottier 1993</a>; <a href="./references#CD003747-bbs2-0026" title="PoniewierskiM , BarthelsM , KuhnM , PoliwodaH . Efficacy of low molecular weight heparin (Fragmin) for thromboprophylaxis in medical patients: A randomized double blind trial [Uber die Wirkamkeit niedermolekularen Heparins (Fragmin) in der Thromboembolieprophylaxe bei internistischen Patienten]. Medizinische Klinische1988;83(7):241‐5. ">Poniewierski 1988</a>; <a href="./references#CD003747-bbs2-0027" title="LederleFA , SacksJM , FioreL , LandefeldCS , SteinbergN , PetersRW , et al. The prophylaxis of medical patients for thromboembolism pilot study. American Journal of Medicine2006;119(1):54‐9. VeteransAdministration . Prophylaxis of medical patients for thromboembolism (PROMPT) study. Veterans Administration Office of Research and Development New Initiatives: Meeting Veterans Needs1999:3. ">PROMPT</a>) from the original review. The reasons for exclusion are detailed in <a href="./references#CD003747-sec-0126" title="">Characteristics of excluded studies</a>. In brief, one study did not strictly fit the criteria for a randomised control trial (<a href="./references#CD003747-bbs2-0021" title="HalkinH , GoldbergJ , ModanM , ModanB . Reduction of mortality in general medical in‐patients by low dose heparin prophylaxis. Annals of Internal Medicine1982;96(5):561‐5. ">Halkin 1982</a>), six studies included patients meeting the exclusion criteria of MI (or acute coronary disease), recent surgery, stroke (or cerebrovascular disease) that could not be removed from the analysis (<a href="./references#CD003747-bbs2-0018" title="CadeJF . High risk of the critically ill for venous thromboembolism. Critical Care Medicine1982;10(7):448‐50. ">Cade 1982a</a>; <a href="./references#CD003747-bbs2-0019" title="CadeJF , AndrewsJT , StubbsAE . Comparison of sodium and calcium heparin in prevention of venous thromboembolism. Australian and New Zealand Journal of Medicine1982;12(5):501‐4. ">Cade 1982b</a>; <a href="./references#CD003747-bbs2-0022" title="HarenbergJ , KallenbachB , MartinU , DempfleCE , ZimmermannR , KublerW , et al. Randomised controlled study of heparin and low molecular weight heparin for prevention of deep vein thrombosis in medical patients. Thrombosis Research1990;59(3):639‐50. ">Harenberg 1990</a>; <a href="./references#CD003747-bbs2-0023" title="HarenbergJ , RoebruckP , HeeneDL , HESIM Group. Prevention of thromboembolism in medical inpatients. Haemostasis1994;24 Suppl 1:36‐Abstract No 36. HarenbergJ , RoebruckP , StehleG , HabscheidW , BiegholdtM , HeeneDL . Heparin Study in Internal Medicine (HESIM): design and preliminary results. Thrombosis Research1992;68(1):33‐43. HarenburgJ , RoebruckP , HeeneDL . Subcutaneous low molecular weight heparin versus standard heparin and the prevention of thromboembolism in medical patients. The Heparin Study in Internal Medicine (HESIM). Haemostasis1996;26(3):127‐39. ">HESIM</a>; <a href="./references#CD003747-bbs2-0025" title="MottierD . Prophylaxis of deep vein thrombosis in medical geriatric patients. Thrombosis and Haemostasis1993;69(6):1115‐Abstract No. 2045. ">Mottier 1993</a>; <a href="./references#CD003747-bbs2-0027" title="LederleFA , SacksJM , FioreL , LandefeldCS , SteinbergN , PetersRW , et al. The prophylaxis of medical patients for thromboembolism pilot study. American Journal of Medicine2006;119(1):54‐9. VeteransAdministration . Prophylaxis of medical patients for thromboembolism (PROMPT) study. Veterans Administration Office of Research and Development New Initiatives: Meeting Veterans Needs1999:3. ">PROMPT</a>), two studies included patients receiving orthopaedic rehabilitation (<a href="./references#CD003747-bbs2-0017" title="AquinoJP , GambierA , DucrosJ . Prevention of thromboembolic accidents in elderly subjects with fraxiparine. In: BounameauxH , SamamaMM , TenCateJW editor(s). Fraxiparine, Second International Symposium Recent Pharmacological and Clinical Data. New York: Schattauer, 1990:51‐4. ">Aquino 1990</a>; <a href="./references#CD003747-bbs2-0024" title="MancietG , VergnesC , VaissieJJ , BoisseauMR . A study of the efficacy and tolerance of fraxiparine during long term therapy of the elderly. A randomized double‐blind clinical trial. In: BounameauxH , SamamaMM , TenCateJW editor(s). Fraxiparine Second International Symposium. Recent Pharmacological and Clinical Data. New York: Schattauer, 1990:55‐9. ">Manciet 1990</a>), one study had all participants receiving the study medication before randomisation to continue the medication or move to placebo (<a href="./references#CD003747-bbs2-0020" title="HullR , SchellongS , TapsonV , YusenR , MonrealM , SamamaMM , et al. Extended thromboprophylaxis with enoxaparin in acutely ill medical patients with prolonged periods of immobilisation: the EXCLAIM study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC397. HullR , TapsonVF , SchellongS , YusenRD , MonrealM , SamamaMM , et al. The EXCLAIM Study: Extended thromboprophylaxis with enoxaparin in acutely ill medical patients with restricted mobility. Blood2003;102(11 (Part 2)):1‐514. HullRD , SchellongS , TapsonV , YusenR , MonrealM , SamamaMM , et al. Extended thromboprophylaxis in acutely ill medical patients with prolonged immobilisation: The EXCLAIM study. Blood2002;100(11):Abstract 3988. HullRD , SchellongSM , TapsonVF , MonrealM , SamamaMM , NicolP , et al. EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended‐duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Annals of Internal Medicine2010;153(1):8‐18. HullRD , SchellongSM , TapsonVF , MonrealM , SamamaMM , TurpieAG , et al. Extended‐duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. Journal of Thrombosis and Thrombolysis2006;22(1):31‐8. HullRD , SchellongSM , TapsonVF , MonrealM , SamamaMM , TurpieAGG , et al. Extended‐duration venous thromboembolism (VTE) prophylaxis in acutely ill medical patients with recent reduced mobility: The EXCLAIM study. XXIst Congress of the International Society of Thrombosis and Haemostasis; 2007 Jul 6‐12; Geneva. 2007. SchellongSM , HullRD , TapsonVF , MonrealM , SamamaMM , TurpieAGG , et al. Extended‐duration enoxaparin for venous thromboembolism prophylaxis in acutely ill medical patients: an evaluation of the EXCLAIM study based on a recently recommended composite efficacy endpoint. Blood2007;110(11):554a. TapsonVF , HullRD , SchellongSM , MonrealM , SamamaMM , TurpieAGG , et al. Consistent venous thromboembolism risk reduction by extended‐ versus standard‐duration enoxaparin prophylaxis in subgroups of acutely ill medical patients in the EXCLAIM study. Blood2007;110(11):552a. YusenRD , HullRD , SchellongSM , TapsonVF , MonrealM , SamamaMM , et al. The effects of the degree of mobility reduction and prespecified risk factors on venous thromboembolism rates in acutely ill medical patients in the EXCLAIM study. Blood2007;110(11):551a. YusenRD , HullRD , SchellongSM , TapsonVF , MonrealM , SamamaMM , et al. The impact of age on the efficacy and safety of extended‐duration thromboprophylaxis in acutely ill medical patients with recent immobility: a sub‐group analysis from the EXCLAIM Study. ASH2009; Vol. 112, issue 11:167. ">EXCLAIM</a>), and one study's method for identifying DVT was not considered sensitive enough (<a href="./references#CD003747-bbs2-0027" title="LederleFA , SacksJM , FioreL , LandefeldCS , SteinbergN , PetersRW , et al. The prophylaxis of medical patients for thromboembolism pilot study. American Journal of Medicine2006;119(1):54‐9. VeteransAdministration . Prophylaxis of medical patients for thromboembolism (PROMPT) study. Veterans Administration Office of Research and Development New Initiatives: Meeting Veterans Needs1999:3. ">PROMPT</a>). </p> </section> </section> <section id="CD003747-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>For details see <a href="#CD003747-fig-0002">Figure 2</a>; <a href="#CD003747-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD003747-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD003747-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003747-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD003747-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <section id="CD003747-sec-0063"> <h4 class="title">Allocation</h4> <p>For random sequence generation five studies were considered low risk (<a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a>; <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>; <a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>; <a href="./references#CD003747-bbs2-0007" title="ForetteB , WolmarkY . Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Presse Medicale1995;24(12):567‐71. ">Forette 1995</a>; <a href="./references#CD003747-bbs2-0012" title="Anon . Study to evaluate the mortality reduction of enoxaparin in hospitalized acutely ill medical receiving enoxaparin (LIFENOX). ClinicalTrials.gov NCT006226482010. KakkarAK , CimminielloC , GoldhaberSZ , ParakhR , WangC , BergmanJ‐F , for the LIFENOX Investigators. Low molecular weight heparin and mortality in acutely ill medical patients. New England Journal of Medicine2011;365(26):2463‐72. ">LIFENOX 2011</a>) and the remaining 11 studies did not give enough information to determine how sequence generation was performed (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0002" title="BergmannJF , CaulinC . Heparin prophylaxis in bedridden patients. Lancet1996;348(9021):205‐6. MaheI , BergmannJF , d'AzemarP , VaissieJJ , CaulinC . Lack of effect of a low‐molecular‐weight heparin (nadroparin) on mortality in bedridden medical in‐patients: a prospective randomised double‐blind study. European Journal of Clinical Pharmacology2005;61(5‐6):347‐51. ">Bergmann 1996</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>; <a href="./references#CD003747-bbs2-0009" title="GallusAS , HirshJ , TuttleRJ , TreblicockR , O'BrienSE , CarrollJJ , et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. New England Journal of Medicine1973;288(11):545‐51. ">Gallus 1973</a>; <a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>; <a href="./references#CD003747-bbs2-0011" title="Ibarra‐PerezC , Lau‐CortesE , Colmenero‐ZubiateS , Arévila‐CeballosN , FongJH , Sánchez‐MartínezR , et al. Prevalence and prevention of deep vein thrombosis of the lower extremities in high risk pulmonary patients. Angiology1988;39(6):505‐13. ">Ibarra‐Perez 1988</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>; <a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>; <a href="./references#CD003747-bbs2-0015" title="KellerF , FlosbachCW , THE PRIME ‐ Study Group. A randomised multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Thrombosis and Haemostasis1995;73(6):1106‐Abstract No 788. LechlerE , SchrammW , FlosbachCW . A randomized, multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised patients. Annals of Hematology1994;68 Suppl 1:A55. LechlerE , SchrammW , FlosbachCW , The PRIME Study Group. The venous thrombotic risk in nonsurgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis1996;26 Suppl 2:49‐56. ">PRIME 1996</a>; <a href="./references#CD003747-bbs2-0016" title="KleberFX , WittC , VogelG , KoppenhagenK , SchomakerU , FlosbachCW , THE‐PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal2003;145(4):614‐21. ">THE‐PRINCE 2003</a>). </p> <p>For allocation concealment, seven studies were considered to be low risk (<a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a>; <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>; <a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>; <a href="./references#CD003747-bbs2-0007" title="ForetteB , WolmarkY . Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Presse Medicale1995;24(12):567‐71. ">Forette 1995</a>; <a href="./references#CD003747-bbs2-0009" title="GallusAS , HirshJ , TuttleRJ , TreblicockR , O'BrienSE , CarrollJJ , et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. New England Journal of Medicine1973;288(11):545‐51. ">Gallus 1973</a>; <a href="./references#CD003747-bbs2-0012" title="Anon . Study to evaluate the mortality reduction of enoxaparin in hospitalized acutely ill medical receiving enoxaparin (LIFENOX). ClinicalTrials.gov NCT006226482010. KakkarAK , CimminielloC , GoldhaberSZ , ParakhR , WangC , BergmanJ‐F , for the LIFENOX Investigators. Low molecular weight heparin and mortality in acutely ill medical patients. New England Journal of Medicine2011;365(26):2463‐72. ">LIFENOX 2011</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>) and the remaining nine studies did not give enough information to understand if allocation was properly concealed (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0002" title="BergmannJF , CaulinC . Heparin prophylaxis in bedridden patients. Lancet1996;348(9021):205‐6. MaheI , BergmannJF , d'AzemarP , VaissieJJ , CaulinC . Lack of effect of a low‐molecular‐weight heparin (nadroparin) on mortality in bedridden medical in‐patients: a prospective randomised double‐blind study. European Journal of Clinical Pharmacology2005;61(5‐6):347‐51. ">Bergmann 1996</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>; <a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>; <a href="./references#CD003747-bbs2-0011" title="Ibarra‐PerezC , Lau‐CortesE , Colmenero‐ZubiateS , Arévila‐CeballosN , FongJH , Sánchez‐MartínezR , et al. Prevalence and prevention of deep vein thrombosis of the lower extremities in high risk pulmonary patients. Angiology1988;39(6):505‐13. ">Ibarra‐Perez 1988</a>; <a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>; <a href="./references#CD003747-bbs2-0015" title="KellerF , FlosbachCW , THE PRIME ‐ Study Group. A randomised multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Thrombosis and Haemostasis1995;73(6):1106‐Abstract No 788. LechlerE , SchrammW , FlosbachCW . A randomized, multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised patients. Annals of Hematology1994;68 Suppl 1:A55. LechlerE , SchrammW , FlosbachCW , The PRIME Study Group. The venous thrombotic risk in nonsurgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis1996;26 Suppl 2:49‐56. ">PRIME 1996</a>; <a href="./references#CD003747-bbs2-0016" title="KleberFX , WittC , VogelG , KoppenhagenK , SchomakerU , FlosbachCW , THE‐PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal2003;145(4):614‐21. ">THE‐PRINCE 2003</a>). </p> </section> <section id="CD003747-sec-0064"> <h4 class="title">Blinding</h4> <p>Adequate blinding is important in reducing the chance of bias in the detection of DVT and PE. Nine trials used double blinding and were considered low risk for performance bias (<a href="./references#CD003747-bbs2-0002" title="BergmannJF , CaulinC . Heparin prophylaxis in bedridden patients. Lancet1996;348(9021):205‐6. MaheI , BergmannJF , d'AzemarP , VaissieJJ , CaulinC . Lack of effect of a low‐molecular‐weight heparin (nadroparin) on mortality in bedridden medical in‐patients: a prospective randomised double‐blind study. European Journal of Clinical Pharmacology2005;61(5‐6):347‐51. ">Bergmann 1996</a>; <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>; <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>; <a href="./references#CD003747-bbs2-0012" title="Anon . Study to evaluate the mortality reduction of enoxaparin in hospitalized acutely ill medical receiving enoxaparin (LIFENOX). ClinicalTrials.gov NCT006226482010. KakkarAK , CimminielloC , GoldhaberSZ , ParakhR , WangC , BergmanJ‐F , for the LIFENOX Investigators. Low molecular weight heparin and mortality in acutely ill medical patients. New England Journal of Medicine2011;365(26):2463‐72. ">LIFENOX 2011</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>; <a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>; <a href="./references#CD003747-bbs2-0015" title="KellerF , FlosbachCW , THE PRIME ‐ Study Group. A randomised multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Thrombosis and Haemostasis1995;73(6):1106‐Abstract No 788. LechlerE , SchrammW , FlosbachCW . A randomized, multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised patients. Annals of Hematology1994;68 Suppl 1:A55. LechlerE , SchrammW , FlosbachCW , The PRIME Study Group. The venous thrombotic risk in nonsurgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis1996;26 Suppl 2:49‐56. ">PRIME 1996</a>). Seven trials were described as open or unblinded, and were therefore at high risk of performance bias (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a>; <a href="./references#CD003747-bbs2-0007" title="ForetteB , WolmarkY . Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Presse Medicale1995;24(12):567‐71. ">Forette 1995</a>; <a href="./references#CD003747-bbs2-0009" title="GallusAS , HirshJ , TuttleRJ , TreblicockR , O'BrienSE , CarrollJJ , et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. New England Journal of Medicine1973;288(11):545‐51. ">Gallus 1973</a>; <a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>; <a href="./references#CD003747-bbs2-0011" title="Ibarra‐PerezC , Lau‐CortesE , Colmenero‐ZubiateS , Arévila‐CeballosN , FongJH , Sánchez‐MartínezR , et al. Prevalence and prevention of deep vein thrombosis of the lower extremities in high risk pulmonary patients. Angiology1988;39(6):505‐13. ">Ibarra‐Perez 1988</a>; <a href="./references#CD003747-bbs2-0016" title="KleberFX , WittC , VogelG , KoppenhagenK , SchomakerU , FlosbachCW , THE‐PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal2003;145(4):614‐21. ">THE‐PRINCE 2003</a>). </p> <p>In nine trials evaluation of the outcomes was undertaken by blinded assessors, and therefore had little risk of detection bias (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a>; <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>; <a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>; <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>; <a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>; <a href="./references#CD003747-bbs2-0012" title="Anon . Study to evaluate the mortality reduction of enoxaparin in hospitalized acutely ill medical receiving enoxaparin (LIFENOX). ClinicalTrials.gov NCT006226482010. KakkarAK , CimminielloC , GoldhaberSZ , ParakhR , WangC , BergmanJ‐F , for the LIFENOX Investigators. Low molecular weight heparin and mortality in acutely ill medical patients. New England Journal of Medicine2011;365(26):2463‐72. ">LIFENOX 2011</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>; <a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>). Six trials did not indicate if the assessors were blinded and therefore had unclear detection bias (<a href="./references#CD003747-bbs2-0002" title="BergmannJF , CaulinC . Heparin prophylaxis in bedridden patients. Lancet1996;348(9021):205‐6. MaheI , BergmannJF , d'AzemarP , VaissieJJ , CaulinC . Lack of effect of a low‐molecular‐weight heparin (nadroparin) on mortality in bedridden medical in‐patients: a prospective randomised double‐blind study. European Journal of Clinical Pharmacology2005;61(5‐6):347‐51. ">Bergmann 1996</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0007" title="ForetteB , WolmarkY . Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Presse Medicale1995;24(12):567‐71. ">Forette 1995</a>; <a href="./references#CD003747-bbs2-0009" title="GallusAS , HirshJ , TuttleRJ , TreblicockR , O'BrienSE , CarrollJJ , et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. New England Journal of Medicine1973;288(11):545‐51. ">Gallus 1973</a>; <a href="./references#CD003747-bbs2-0011" title="Ibarra‐PerezC , Lau‐CortesE , Colmenero‐ZubiateS , Arévila‐CeballosN , FongJH , Sánchez‐MartínezR , et al. Prevalence and prevention of deep vein thrombosis of the lower extremities in high risk pulmonary patients. Angiology1988;39(6):505‐13. ">Ibarra‐Perez 1988</a>; <a href="./references#CD003747-bbs2-0015" title="KellerF , FlosbachCW , THE PRIME ‐ Study Group. A randomised multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Thrombosis and Haemostasis1995;73(6):1106‐Abstract No 788. LechlerE , SchrammW , FlosbachCW . A randomized, multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised patients. Annals of Hematology1994;68 Suppl 1:A55. LechlerE , SchrammW , FlosbachCW , The PRIME Study Group. The venous thrombotic risk in nonsurgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis1996;26 Suppl 2:49‐56. ">PRIME 1996</a>). For <a href="./references#CD003747-bbs2-0016" title="KleberFX , WittC , VogelG , KoppenhagenK , SchomakerU , FlosbachCW , THE‐PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal2003;145(4):614‐21. ">THE‐PRINCE 2003</a> study the authors clearly stated that the efficacy endpoints were evaluated by blinded assessors and was therefore at low risk of detection bias, but the safety endpoints were not included in this description so they had an unclear risk of detection bias. </p> </section> <section id="CD003747-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <p>Twelve studies included all randomised participants in the analysis or clearly described how many participants were excluded from each group and why, and that the treatment groups remained similar after the exclusions (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0002" title="BergmannJF , CaulinC . Heparin prophylaxis in bedridden patients. Lancet1996;348(9021):205‐6. MaheI , BergmannJF , d'AzemarP , VaissieJJ , CaulinC . Lack of effect of a low‐molecular‐weight heparin (nadroparin) on mortality in bedridden medical in‐patients: a prospective randomised double‐blind study. European Journal of Clinical Pharmacology2005;61(5‐6):347‐51. ">Bergmann 1996</a>; <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>; <a href="./references#CD003747-bbs2-0007" title="ForetteB , WolmarkY . Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Presse Medicale1995;24(12):567‐71. ">Forette 1995</a>; <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>; <a href="./references#CD003747-bbs2-0009" title="GallusAS , HirshJ , TuttleRJ , TreblicockR , O'BrienSE , CarrollJJ , et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. New England Journal of Medicine1973;288(11):545‐51. ">Gallus 1973</a>; <a href="./references#CD003747-bbs2-0012" title="Anon . Study to evaluate the mortality reduction of enoxaparin in hospitalized acutely ill medical receiving enoxaparin (LIFENOX). ClinicalTrials.gov NCT006226482010. KakkarAK , CimminielloC , GoldhaberSZ , ParakhR , WangC , BergmanJ‐F , for the LIFENOX Investigators. Low molecular weight heparin and mortality in acutely ill medical patients. New England Journal of Medicine2011;365(26):2463‐72. ">LIFENOX 2011</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>; <a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>; <a href="./references#CD003747-bbs2-0015" title="KellerF , FlosbachCW , THE PRIME ‐ Study Group. A randomised multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Thrombosis and Haemostasis1995;73(6):1106‐Abstract No 788. LechlerE , SchrammW , FlosbachCW . A randomized, multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised patients. Annals of Hematology1994;68 Suppl 1:A55. LechlerE , SchrammW , FlosbachCW , The PRIME Study Group. The venous thrombotic risk in nonsurgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis1996;26 Suppl 2:49‐56. ">PRIME 1996</a>). These 12 studies were considered low risk for attrition bias. Two studies did not include enough information about incomplete outcome data to determine whether or not there was a risk of attrition bias (<a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>; <a href="./references#CD003747-bbs2-0011" title="Ibarra‐PerezC , Lau‐CortesE , Colmenero‐ZubiateS , Arévila‐CeballosN , FongJH , Sánchez‐MartínezR , et al. Prevalence and prevention of deep vein thrombosis of the lower extremities in high risk pulmonary patients. Angiology1988;39(6):505‐13. ">Ibarra‐Perez 1988</a>). In the <a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a> study the efficacy endpoints had unclear risk as there were missing participants unaccounted for in the analysis, but there was a low risk of attrition bias for the safety endpoints as all participants were considered in this analysis. For <a href="./references#CD003747-bbs2-0016" title="KleberFX , WittC , VogelG , KoppenhagenK , SchomakerU , FlosbachCW , THE‐PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal2003;145(4):614‐21. ">THE‐PRINCE 2003</a> study the study authors described inequality between the study groups for the reasons why participants withdrew and were not included in the analysis, leading to high risk of attrition bias for these outcomes. However, the safety endpoints in this study were at a low risk of attrition bias because all participants were reported on. </p> </section> <section id="CD003747-sec-0066"> <h4 class="title">Selective reporting</h4> <p>Fifteen of the 16 studies have low risk of reporting bias because they either followed the provided protocol or there was no evidence of selective outcome reporting. The <a href="./references#CD003747-bbs2-0002" title="BergmannJF , CaulinC . Heparin prophylaxis in bedridden patients. Lancet1996;348(9021):205‐6. MaheI , BergmannJF , d'AzemarP , VaissieJJ , CaulinC . Lack of effect of a low‐molecular‐weight heparin (nadroparin) on mortality in bedridden medical in‐patients: a prospective randomised double‐blind study. European Journal of Clinical Pharmacology2005;61(5‐6):347‐51. ">Bergmann 1996</a> study was considered to have unclear risk of reporting bias because in the limited report available it was unclear whether the mortality reported was all‐cause or specifically due to thromboembolism. </p> </section> <section id="CD003747-sec-0067"> <h4 class="title">Other potential sources of bias</h4> <p>Seven studies reported support by large pharmaceutical companies, which could have potentially introduced bias (<a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a>; <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>; <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>; <a href="./references#CD003747-bbs2-0012" title="Anon . Study to evaluate the mortality reduction of enoxaparin in hospitalized acutely ill medical receiving enoxaparin (LIFENOX). ClinicalTrials.gov NCT006226482010. KakkarAK , CimminielloC , GoldhaberSZ , ParakhR , WangC , BergmanJ‐F , for the LIFENOX Investigators. Low molecular weight heparin and mortality in acutely ill medical patients. New England Journal of Medicine2011;365(26):2463‐72. ">LIFENOX 2011</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>; <a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>; <a href="./references#CD003747-bbs2-0016" title="KleberFX , WittC , VogelG , KoppenhagenK , SchomakerU , FlosbachCW , THE‐PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal2003;145(4):614‐21. ">THE‐PRINCE 2003</a>). </p> </section> </section> <section id="CD003747-sec-0068"> <h3 class="title" id="CD003747-sec-0068">Effects of interventions</h3> <section id="CD003747-sec-0069"> <h4 class="title">Heparin (LMWH and UFH) versus placebo or no treatment</h4> <section id="CD003747-sec-0070"> <h5 class="title">Efficacy</h5> <section id="CD003747-sec-0071"> <h6 class="title">Deep vein thrombosis (DVT)</h6> <p>Data were available for DVT in seven trials (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>; <a href="./references#CD003747-bbs2-0009" title="GallusAS , HirshJ , TuttleRJ , TreblicockR , O'BrienSE , CarrollJJ , et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. New England Journal of Medicine1973;288(11):545‐51. ">Gallus 1973</a>; <a href="./references#CD003747-bbs2-0011" title="Ibarra‐PerezC , Lau‐CortesE , Colmenero‐ZubiateS , Arévila‐CeballosN , FongJH , Sánchez‐MartínezR , et al. Prevalence and prevention of deep vein thrombosis of the lower extremities in high risk pulmonary patients. Angiology1988;39(6):505‐13. ">Ibarra‐Perez 1988</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>; <a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>). The heparin treatment group had reduced odds of DVT (OR 0.41; 95% CI 0.25 to 0.67; P = 0.0004). When sensitivity analysis was performed to assess the effects of a loss of ≥ 20% of the study population, the <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a> and <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a> studies were removed and there was little effect on the results with an OR of 0.26 (95% CI 0.12 to 0.54; P = 0.0004). By removing <a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a> and <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a> for sensitivity analysis for low‐accuracy testing of DVT there was little effect on the overall outcome with an OR of 0.48 (95% CI 0.29 to 0.81; P = 0.006). Removing the low‐dose enoxaparin group from the <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a> study, there was only a slight variation in the analyses (OR 0.37; 95% CI 0.25 to 0.55; P &lt; 0.00001). </p> </section> <section id="CD003747-sec-0072"> <h6 class="title">Pulmonary embolism (PE)</h6> <p>Symptomatic, non‐fatal PE was measured in seven trials (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>; <a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>; <a href="./references#CD003747-bbs2-0011" title="Ibarra‐PerezC , Lau‐CortesE , Colmenero‐ZubiateS , Arévila‐CeballosN , FongJH , Sánchez‐MartínezR , et al. Prevalence and prevention of deep vein thrombosis of the lower extremities in high risk pulmonary patients. Angiology1988;39(6):505‐13. ">Ibarra‐Perez 1988</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>; <a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>). Meta‐analysis was only conducted for six, excluding <a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a> as non‐fatal PE was only assessed through necropsy data and not in all participants. Non‐fatal PE had an OR of 0.46 (95% CI 0.20 to 1.07; P = 0.07). Fatal PE was recorded in six trials (<a href="./references#CD003747-bbs2-0002" title="BergmannJF , CaulinC . Heparin prophylaxis in bedridden patients. Lancet1996;348(9021):205‐6. MaheI , BergmannJF , d'AzemarP , VaissieJJ , CaulinC . Lack of effect of a low‐molecular‐weight heparin (nadroparin) on mortality in bedridden medical in‐patients: a prospective randomised double‐blind study. European Journal of Clinical Pharmacology2005;61(5‐6):347‐51. ">Bergmann 1996</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>; <a href="./references#CD003747-bbs2-0012" title="Anon . Study to evaluate the mortality reduction of enoxaparin in hospitalized acutely ill medical receiving enoxaparin (LIFENOX). ClinicalTrials.gov NCT006226482010. KakkarAK , CimminielloC , GoldhaberSZ , ParakhR , WangC , BergmanJ‐F , for the LIFENOX Investigators. Low molecular weight heparin and mortality in acutely ill medical patients. New England Journal of Medicine2011;365(26):2463‐72. ">LIFENOX 2011</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>; <a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>) with an OR of 0.71 (95% CI 0.43 to 1.15; P = 0.16). Combined non‐fatal PE and fatal PE was reported for nine studies (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0002" title="BergmannJF , CaulinC . Heparin prophylaxis in bedridden patients. Lancet1996;348(9021):205‐6. MaheI , BergmannJF , d'AzemarP , VaissieJJ , CaulinC . Lack of effect of a low‐molecular‐weight heparin (nadroparin) on mortality in bedridden medical in‐patients: a prospective randomised double‐blind study. European Journal of Clinical Pharmacology2005;61(5‐6):347‐51. ">Bergmann 1996</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>; <a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>; <a href="./references#CD003747-bbs2-0011" title="Ibarra‐PerezC , Lau‐CortesE , Colmenero‐ZubiateS , Arévila‐CeballosN , FongJH , Sánchez‐MartínezR , et al. Prevalence and prevention of deep vein thrombosis of the lower extremities in high risk pulmonary patients. Angiology1988;39(6):505‐13. ">Ibarra‐Perez 1988</a>; <a href="./references#CD003747-bbs2-0012" title="Anon . Study to evaluate the mortality reduction of enoxaparin in hospitalized acutely ill medical receiving enoxaparin (LIFENOX). ClinicalTrials.gov NCT006226482010. KakkarAK , CimminielloC , GoldhaberSZ , ParakhR , WangC , BergmanJ‐F , for the LIFENOX Investigators. Low molecular weight heparin and mortality in acutely ill medical patients. New England Journal of Medicine2011;365(26):2463‐72. ">LIFENOX 2011</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>; <a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>) with an OR of 0.66 (95% CI 0.43 to 1.02; P = 0.06). When the <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a> and <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a> studies were removed for sensitivity analysis to assess the effects of a loss of ≥ 20% of the study population, there was little change in results for non‐fatal PE (OR 0.55; 95% CI 0.22 to 1.39; P = 0.20), no change for fatal PE as neither study was contributing, and there was no difference between the treatment groups for combined non‐fatal and fatal PE (OR 0.68 95% CI 0.44 to 1.07; P = 0.09). When the 20 mg enoxaparin treatment group in the <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a> study was removed there was a small change on non‐fatal PE (OR 0.50; 95% CI 0.21 to 1.20; P = 0.12), no change for fatal PE, and almost no change for combined non‐fatal and fatal PE (OR 0.66; 95% CI 0.43 to 1.03; P = 0.07). </p> </section> <section id="CD003747-sec-0073"> <h6 class="title">All‐cause mortality</h6> <p>All‐cause mortality was assessed in eight trials (<a href="./references#CD003747-bbs2-0002" title="BergmannJF , CaulinC . Heparin prophylaxis in bedridden patients. Lancet1996;348(9021):205‐6. MaheI , BergmannJF , d'AzemarP , VaissieJJ , CaulinC . Lack of effect of a low‐molecular‐weight heparin (nadroparin) on mortality in bedridden medical in‐patients: a prospective randomised double‐blind study. European Journal of Clinical Pharmacology2005;61(5‐6):347‐51. ">Bergmann 1996</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>; <a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>; <a href="./references#CD003747-bbs2-0011" title="Ibarra‐PerezC , Lau‐CortesE , Colmenero‐ZubiateS , Arévila‐CeballosN , FongJH , Sánchez‐MartínezR , et al. Prevalence and prevention of deep vein thrombosis of the lower extremities in high risk pulmonary patients. Angiology1988;39(6):505‐13. ">Ibarra‐Perez 1988</a>; <a href="./references#CD003747-bbs2-0012" title="Anon . Study to evaluate the mortality reduction of enoxaparin in hospitalized acutely ill medical receiving enoxaparin (LIFENOX). ClinicalTrials.gov NCT006226482010. KakkarAK , CimminielloC , GoldhaberSZ , ParakhR , WangC , BergmanJ‐F , for the LIFENOX Investigators. Low molecular weight heparin and mortality in acutely ill medical patients. New England Journal of Medicine2011;365(26):2463‐72. ">LIFENOX 2011</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>; <a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>) but meta‐analysis was only performed for seven, excluding <a href="./references#CD003747-bbs2-0011" title="Ibarra‐PerezC , Lau‐CortesE , Colmenero‐ZubiateS , Arévila‐CeballosN , FongJH , Sánchez‐MartínezR , et al. Prevalence and prevention of deep vein thrombosis of the lower extremities in high risk pulmonary patients. Angiology1988;39(6):505‐13. ">Ibarra‐Perez 1988</a> because not enough information was given to fully understand which treatment groups the deaths occurred in. There was no clear evidence of a difference in mortality between the two treatment groups, with an OR of 0.97 (95% CI 0.87 to 1.08; P = 0.57). When the <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a> study's 20 mg enoxaparin treatment group was removed in a sensitivity analysis there was no change to the results of the analyses. </p> </section> </section> <section id="CD003747-sec-0074"> <h5 class="title">Safety</h5> <section id="CD003747-sec-0075"> <h6 class="title">Bleeding</h6> <p>Major bleeding was evaluated in eight studies (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>; <a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>; <a href="./references#CD003747-bbs2-0011" title="Ibarra‐PerezC , Lau‐CortesE , Colmenero‐ZubiateS , Arévila‐CeballosN , FongJH , Sánchez‐MartínezR , et al. Prevalence and prevention of deep vein thrombosis of the lower extremities in high risk pulmonary patients. Angiology1988;39(6):505‐13. ">Ibarra‐Perez 1988</a>; <a href="./references#CD003747-bbs2-0012" title="Anon . Study to evaluate the mortality reduction of enoxaparin in hospitalized acutely ill medical receiving enoxaparin (LIFENOX). ClinicalTrials.gov NCT006226482010. KakkarAK , CimminielloC , GoldhaberSZ , ParakhR , WangC , BergmanJ‐F , for the LIFENOX Investigators. Low molecular weight heparin and mortality in acutely ill medical patients. New England Journal of Medicine2011;365(26):2463‐72. ">LIFENOX 2011</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>; <a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>) but meta‐analysis was conducted using only seven trials, excluding <a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>. This was for the same reason as for the outcome of non‐fatal PE: major bleeding was only evaluated through necropsy data and was not evaluated in all patients. Heparin was associated with an increase in major bleeding (OR 1.65; 95% CI 1.01 to 2.71; P = 0.05). When sensitivity analysis was performed by removing studies with inadequate definitions of the major bleeding, <a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a> and <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>, the association was more precise (OR 1.83; 95% CI 1.09 to 3.07; P = 0.02). Minor bleeding was evaluated in five studies (<a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>; <a href="./references#CD003747-bbs2-0011" title="Ibarra‐PerezC , Lau‐CortesE , Colmenero‐ZubiateS , Arévila‐CeballosN , FongJH , Sánchez‐MartínezR , et al. Prevalence and prevention of deep vein thrombosis of the lower extremities in high risk pulmonary patients. Angiology1988;39(6):505‐13. ">Ibarra‐Perez 1988</a>; <a href="./references#CD003747-bbs2-0012" title="Anon . Study to evaluate the mortality reduction of enoxaparin in hospitalized acutely ill medical receiving enoxaparin (LIFENOX). ClinicalTrials.gov NCT006226482010. KakkarAK , CimminielloC , GoldhaberSZ , ParakhR , WangC , BergmanJ‐F , for the LIFENOX Investigators. Low molecular weight heparin and mortality in acutely ill medical patients. New England Journal of Medicine2011;365(26):2463‐72. ">LIFENOX 2011</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>; <a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>) and heparin was associated with significantly increased odds of 1.61 (95% CI 1.26 to 2.08; P = 0.0002). When the low dose of enoxaparin in the <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a> study was removed, the major bleeding outcome had stronger statistical significance (OR 1.81; 95% CI 1.09 to 3.03; P = 0.02) but there was very little change in the minor bleeding outcome (OR 1.61; 95% CI 1.23 to 2.12; P = 0.0006). </p> </section> <section id="CD003747-sec-0076"> <h6 class="title">Thrombocytopaenia</h6> <p>Thrombocytopaenia was measured in four studies (<a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>; <a href="./references#CD003747-bbs2-0012" title="Anon . Study to evaluate the mortality reduction of enoxaparin in hospitalized acutely ill medical receiving enoxaparin (LIFENOX). ClinicalTrials.gov NCT006226482010. KakkarAK , CimminielloC , GoldhaberSZ , ParakhR , WangC , BergmanJ‐F , for the LIFENOX Investigators. Low molecular weight heparin and mortality in acutely ill medical patients. New England Journal of Medicine2011;365(26):2463‐72. ">LIFENOX 2011</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>; <a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>). There was no clear evidence of a difference between the two groups for thrombocytopaenia (OR 1.05; 95% CI 0.64 to 1.74; P = 0.85). Removing the low‐dose enoxaparin treatment group from the <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a> study had little effect on the overall outcome (OR 1.12; 95% CI 0.63 to 2.00; P = 0.69). </p> </section> <section id="CD003747-sec-0077"> <h6 class="title">Heterogeneity and reporting bias</h6> <p>For the comparison between heparin and placebo or no treatment there was little or no heterogeneity between the studies, therefore all meta‐analyses, except for the DVT outcome, were conducted using a fixed‐effect model. The DVT outcome was analysed using a random‐effects model but when the 20 mg enoxaparin treatment group in the <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a> study was removed for sensitivity analysis a fixed‐effect model was able to be utilised. None of the comparisons had 10 or more studies so an assessment for reporting bias by constructing funnel plots could not be performed. </p> </section> </section> </section> <section id="CD003747-sec-0078"> <h4 class="title">LMWH versus UFH</h4> <section id="CD003747-sec-0079"> <h5 class="title">Efficacy</h5> <section id="CD003747-sec-0080"> <h6 class="title">Deep vein thrombosis (DVT)</h6> <p>Six studies evaluated DVT (<a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a>; <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>; <a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>; <a href="./references#CD003747-bbs2-0007" title="ForetteB , WolmarkY . Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Presse Medicale1995;24(12):567‐71. ">Forette 1995</a>; <a href="./references#CD003747-bbs2-0015" title="KellerF , FlosbachCW , THE PRIME ‐ Study Group. A randomised multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Thrombosis and Haemostasis1995;73(6):1106‐Abstract No 788. LechlerE , SchrammW , FlosbachCW . A randomized, multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised patients. Annals of Hematology1994;68 Suppl 1:A55. LechlerE , SchrammW , FlosbachCW , The PRIME Study Group. The venous thrombotic risk in nonsurgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis1996;26 Suppl 2:49‐56. ">PRIME 1996</a>; <a href="./references#CD003747-bbs2-0016" title="KleberFX , WittC , VogelG , KoppenhagenK , SchomakerU , FlosbachCW , THE‐PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal2003;145(4):614‐21. ">THE‐PRINCE 2003</a>). For the LMWH treatment group there was a decreased odds compared to the UFH group (OR 0.77; 95% CI 0.62 to 0.96; P = 0.02). When the <a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a> and <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a> were removed for sensitivity analysis to assess the effects of a loss of ≥ 20% of the study population, there was no longer any evidence of a difference between the treatment groups (OR 0.80; 95% CI 0.50 to 1.29; P = 0.37). Removing <a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a> for sensitivity analysis for both a low‐accuracy test for DVT and low dosage of enoxaparin, there was very little effect on the overall outcome (OR 0.76; 95% CI 0.61 to 0.96; P = 0.02). </p> </section> <section id="CD003747-sec-0081"> <h6 class="title">Pulmonary embolism (PE)</h6> <p>Symptomatic, non‐fatal PE was measured in six studies (<a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a>; <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>; <a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>; <a href="./references#CD003747-bbs2-0007" title="ForetteB , WolmarkY . Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Presse Medicale1995;24(12):567‐71. ">Forette 1995</a>; <a href="./references#CD003747-bbs2-0015" title="KellerF , FlosbachCW , THE PRIME ‐ Study Group. A randomised multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Thrombosis and Haemostasis1995;73(6):1106‐Abstract No 788. LechlerE , SchrammW , FlosbachCW . A randomized, multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised patients. Annals of Hematology1994;68 Suppl 1:A55. LechlerE , SchrammW , FlosbachCW , The PRIME Study Group. The venous thrombotic risk in nonsurgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis1996;26 Suppl 2:49‐56. ">PRIME 1996</a>; <a href="./references#CD003747-bbs2-0016" title="KleberFX , WittC , VogelG , KoppenhagenK , SchomakerU , FlosbachCW , THE‐PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal2003;145(4):614‐21. ">THE‐PRINCE 2003</a>). There was no clear evidence of a difference between LMWH and UFH for non‐fatal PE (OR 0.93; 95% CI 0.42 to 2.08; P = 0.86). Fatal PE was measured in only two studies (<a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a>; <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>) for which there was no difference between the two treatment groups (OR 0.33; 95% CI 0.01 to 8.13; P = 0.50). Combined non‐fatal and fatal PE was evaluated in the same six studies as non‐fatal PE, with no evidence of a difference between UFH and LMWH (OR 0.86; 95% CI 0.39 to 1.90; P = 0.71). When <a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a> and <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a> were removed for sensitivity analysis to assess the effects of a loss of ≥ 20% of the study population, the non‐fatal PE OR was lowered to 0.47, but the association remained non‐significant (95% CI 0.13 to 1.68; P = 0.25). As <a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a> and <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a> were the only two studies evaluated for fatal PE, this outcome was no longer estimable and the combined non‐fatal and fatal PE was identical to non‐fatal PE. </p> </section> <section id="CD003747-sec-0082"> <h6 class="title">All‐cause mortality</h6> <p>All‐cause mortality was assessed in five studies (<a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>; <a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>; <a href="./references#CD003747-bbs2-0007" title="ForetteB , WolmarkY . Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Presse Medicale1995;24(12):567‐71. ">Forette 1995</a>; <a href="./references#CD003747-bbs2-0015" title="KellerF , FlosbachCW , THE PRIME ‐ Study Group. A randomised multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Thrombosis and Haemostasis1995;73(6):1106‐Abstract No 788. LechlerE , SchrammW , FlosbachCW . A randomized, multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised patients. Annals of Hematology1994;68 Suppl 1:A55. LechlerE , SchrammW , FlosbachCW , The PRIME Study Group. The venous thrombotic risk in nonsurgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis1996;26 Suppl 2:49‐56. ">PRIME 1996</a>; <a href="./references#CD003747-bbs2-0016" title="KleberFX , WittC , VogelG , KoppenhagenK , SchomakerU , FlosbachCW , THE‐PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal2003;145(4):614‐21. ">THE‐PRINCE 2003</a>). There was no clear evidence for a difference in mortality (OR 0.79; 95% CI 0.54 to 1.16; P = 0.23). </p> </section> </section> <section id="CD003747-sec-0083"> <h5 class="title">Safety</h5> <section id="CD003747-sec-0084"> <h6 class="title">Bleeding</h6> <p>Six studies measured major bleeding as an outcome (<a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a>; <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>; <a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>; <a href="./references#CD003747-bbs2-0007" title="ForetteB , WolmarkY . Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Presse Medicale1995;24(12):567‐71. ">Forette 1995</a>; <a href="./references#CD003747-bbs2-0015" title="KellerF , FlosbachCW , THE PRIME ‐ Study Group. A randomised multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Thrombosis and Haemostasis1995;73(6):1106‐Abstract No 788. LechlerE , SchrammW , FlosbachCW . A randomized, multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised patients. Annals of Hematology1994;68 Suppl 1:A55. LechlerE , SchrammW , FlosbachCW , The PRIME Study Group. The venous thrombotic risk in nonsurgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis1996;26 Suppl 2:49‐56. ">PRIME 1996</a>; <a href="./references#CD003747-bbs2-0016" title="KleberFX , WittC , VogelG , KoppenhagenK , SchomakerU , FlosbachCW , THE‐PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal2003;145(4):614‐21. ">THE‐PRINCE 2003</a>). There was a reduced odds found in the LMWH group compared with the UFH group (OR 0.43; 95% CI 0.22 to 0.83; P = 0.01). Minor bleeding was assessed in three studies (<a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a>; <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>; <a href="./references#CD003747-bbs2-0007" title="ForetteB , WolmarkY . Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Presse Medicale1995;24(12):567‐71. ">Forette 1995</a>) and was associated with an imprecise decreased odds with LMWH (OR 0.70; 95% CI 0.48 to 1.00; P = 0.05), possibly a chance effect. When the <a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a> study was removed for sensitivity analysis to assess the effect of the longer follow‐up time period, there was little change for major bleeding (OR 0.43; 95% CI 0.22 to 0.87; P = 0.02) and minor bleeding moved from a possible chance effect to statistically significant (OR 0.66; 95% CI 0.45 to 0.96; P = 0.03). </p> </section> <section id="CD003747-sec-0085"> <h6 class="title">Thrombocytopaenia</h6> <p>Thrombocytopaenia was evaluated in three studies (<a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a>; <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>; <a href="./references#CD003747-bbs2-0007" title="ForetteB , WolmarkY . Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Presse Medicale1995;24(12):567‐71. ">Forette 1995</a>). There was no difference between LMWH and UFH (OR 0.41; 95% CI 0.08 to 2.11; P = 0.28). When sensitivity analysis was performed by removing the <a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a> study to assess the effects of the longer follow‐up period, there was very little change (OR 0.43; 95% CI 0.06 to 2.92; P = 0.39). </p> </section> <section id="CD003747-sec-0086"> <h6 class="title">Heterogeneity and reporting bias</h6> <p>For the comparison between UFH and LMWH there was little or no heterogeneity between the studies, therefore all meta‐analyses were conducted using a fixed‐effect model. None of the comparisons had 10 or more studies so an assessment for reporting bias by using a funnel plot could not be performed. </p> </section> <section id="CD003747-sec-0087"> <h6 class="title">Subgroup analysis</h6> <p>Subgroup analysis based on medical diagnosis at hospital admission could not be performed as there are currently insufficient data within published studies on outcomes within subgroups of interest. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003747-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003747-sec-0088"></div> <section id="CD003747-sec-0089"> <h3 class="title" id="CD003747-sec-0089">Summary of main results</h3> <p>Heparin resulted in a reduction in DVT but no difference in non‐fatal and/or fatal PE (separately and combined) when compared with placebo or no treatment. The reduction in VTE risk is comparable to that previously reported in prophylaxis studies of patients following acute myocardial infarction (<a href="./references#CD003747-bbs2-0036" title="CollinsR , MacMahonS , FlatherM , BaigentC , RemvigL , MortensenS , et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ1996;313(7058):652‐9. ">Collins 1996</a>), acute ischaemic stroke (<a href="./references#CD003747-bbs2-0043" title="GubitzG , SandercockP , CounsellC . Anticoagulants for acute ischaemic stroke (Review). Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD000024.pub2] ">Gubitz 2004</a>), colorectal surgery (<a href="./references#CD003747-bbs2-0055" title="Wille‐JørgensenP , RasmussenMS , AndersenBR , BorlyL . Heparins and mechanical methods for thromboprophylaxis in colorectal surgery (Review). Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD001217] ">Wille‐Jørgensen 2004</a>) and orthopaedic surgery (<a href="./references#CD003747-bbs2-0035" title="CollinsR , ScrimgeourA , YusufS , PetoR . Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. New England Journal of Medicine1988;318(18):1162‐73. ">Collins 1988</a>). </p> <p>The analysis found no clear difference in all‐cause mortality in patients receiving heparin prophylaxis. However, these studies are not powered to show a difference in mortality, which would require over 200,000 patients (assuming an overall 5% mortality, 10% of deaths due to VTE, and a 50% relative risk (RR) reduction in events). </p> <p>In the presence of heparin prophylaxis the rate of major haemorrhage (0.64%) was higher than with no prophylaxis (0.36%). LMWH resulted in less major haemorrhage than UFH. This suggests a favourable benefit‐risk ratio for LMWH therapy in the prevention of VTE in general medical patients. </p> <p>In summary, patients hospitalised with an acute medical illness who receive UFH or LMWH thromboprophylaxis have a reduced risk of DVT, however there is an increase in major haemorrhage when compared to those who do not receive chemical thromboprophylaxis. LMWH reduced the odds of DVT compared with UFH as well as reduced the odds of major bleeding, suggesting LMWH has a better efficacy profile and carries a lower risk of adverse events compared with UFH. There are currently insufficient published data to allow analysis of outcomes of interest based on patient medical diagnosis at hospital admission. </p> </section> <section id="CD003747-sec-0090"> <h3 class="title" id="CD003747-sec-0090">Overall completeness and applicability of evidence</h3> <p>The conclusions provided in this analysis have a strong external application as the evidence was generated using 16 good quality studies that were sufficient to address the study outcomes. The 16 studies included 34,369 participants from at least 17 different countries, with the majority of studies being multi‐centre, and four being multi‐national. </p> <p>Although this review does not identify heparin as preventing all‐cause mortality in patients with an acute medical illness, it does appear to show a benefit in reducing DVT and possibly the combined outcome of symptomatic PE and fatal PE. Therefore, in patients with an acute medical illness heparin appears to reduce the risk of hospital acquired thrombosis (HAT), supporting the current medical practice of increasing awareness and advocating VTE prevention (<a href="./references#CD003747-bbs2-0052" title="National Institute for Health and Care Excellence (NICE). Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital, Clinical guidelines CG92. NICE2010:http://guidance.nice.org.uk/CG92. ">NICE</a>). </p> <p>Currently, published studies are lacking outcome data specific to medical diagnosis at hospital admission. These data would help us to understand if certain patients, based on disease, would benefit more or less from thromboprophylaxis or are at a higher or lower risk of bleeding. Understanding these differences would help develop a stronger profile for the use of thromboprophylaxis in acutely ill medical patients. </p> <p>Patients who develop VTE following an acute medical illness have a more severe presentation and significantly worse outcome than patients who develop VTE following surgery (<a href="./references#CD003747-bbs2-0051" title="MonrealM , KakkarAK , CapriniJA , BarbaR , UresandiF , ValleR , et al. RIETE Investigators. The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE registry. Journal of Thrombosis and Haemostasis2004;2(11):1892‐8. ">Monreal 2004</a>). Venous thromboembolic disease in hospitalised medical patients is a preventable occurrence and is associated with unacceptably high levels of morbidity and mortality. </p> <p>In a report by the House of Commons Health Committee, it was recommended that "VTE and its prevention, including the implementation of, and adherence to guidelines relating to thromboprophylaxis, counselling and risk assessment, be given more prominence in undergraduate medical education, continuing professional development, and other relevant aspects of medical and paramedical training" (<a href="./references#CD003747-bbs2-0044" title="House of Commons Health Committee. The prevention of venous thromboembolism in hospitalised patients. London: The Stationery Office Ltd, 2005. ">Health Committee 2005</a>). </p> <p>The current 'Prevention of VTE' guidelines presented by the American College of Chest Physicians also stress the importance of all hospitals having formal, written guidelines for thromboprophylaxis and that all patients undergo VTE risk assessment (<a href="./references#CD003747-bbs2-0047" title="KahnSR , LimW , DunnAS , CushmanM , DentaliF , AklEA , et al. American College of Chest Physicians. Prevention of VTE in non surgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence‐based clinical practice guidelines. Chest2012;141(2 Suppl):e195S‐226S. ">Kahn 2012</a>). </p> <p>Current medical practice concerning VTE emphasizes awareness of HAT, with appreciation for the risk of VTE increasing dramatically within the past decade. All patients admitted to hospital with an acute medical illness should be risk assessed and thromboprophylaxis offered to those perceived to be at increased risk of VTE. In fact, patients are actively encouraged to question their admitting physicians as to their individual VTE risk and need for thromboprophylaxis (<a href="./references#CD003747-bbs2-0052" title="National Institute for Health and Care Excellence (NICE). Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital, Clinical guidelines CG92. NICE2010:http://guidance.nice.org.uk/CG92. ">NICE</a>) in an attempt to reduce the risk of HAT. </p> </section> <section id="CD003747-sec-0091"> <h3 class="title" id="CD003747-sec-0091">Quality of the evidence</h3> <p>Sixteen studies were used to compile evidence, 10 comparing heparin prophylaxis with no treatment or placebo and six which compared LMWH to UFH, with a total of 34,369 participants. For the majority of the outcomes there was general agreement between the studies. Overall quality of the studies was good, with concern for performance bias in the studies that were open label, which made up just under half of the studies. Also, most of the studies were lacking in an explanation of how random sequence generation and allocation concealment were performed, although this is most likely due to the fact that many included studies are older and were not held to as high reporting standards when published. </p> </section> <section id="CD003747-sec-0092"> <h3 class="title" id="CD003747-sec-0092">Potential biases in the review process</h3> <p>All data used were dichotomous, therefore little data manipulation that could introduce bias was required for analysis. However, for the <a href="./references#CD003747-bbs2-0002" title="BergmannJF , CaulinC . Heparin prophylaxis in bedridden patients. Lancet1996;348(9021):205‐6. MaheI , BergmannJF , d'AzemarP , VaissieJJ , CaulinC . Lack of effect of a low‐molecular‐weight heparin (nadroparin) on mortality in bedridden medical in‐patients: a prospective randomised double‐blind study. European Journal of Clinical Pharmacology2005;61(5‐6):347‐51. ">Bergmann 1996</a> study all‐cause mortality data were calculated using provided percentages and were transformed into dichotomous values for the purposes of the meta‐analysis. </p> <p>In order to reduce bias, both the 20 mg and 40 mg enoxaparin groups from <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a> were included in the meta‐analysis. To avoid double‐counting of participants, the participants and events within the comparison (placebo) group were split evenly between the two treatment groups, rounding down for odd numbers. </p> <p>While all attempts to include relevant studies were made by the review authors, it is possible pertinent data were overlooked. </p> </section> <section id="CD003747-sec-0093"> <h3 class="title" id="CD003747-sec-0093">Agreements and disagreements with other studies or reviews</h3> <p>Several meta‐analysis are available on this topic.</p> <p><a href="./references#CD003747-bbs2-0050" title="MismettiP , Laporte‐SimitsidisS , TardyB , CucheratM , BuchmullerA , Juillard‐DelsartD , et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low molecular weight heparins: a meta‐analysis of randomised clinical trials. Thrombosis and Hemostasis2000;83(1):14‐9. ">Mismetti 2000</a> </p> <p>The findings of this review are in keeping with the meta‐analysis published by Mismeti et al, which assessed seven trials comparing prophylactic heparin to control and nine trials comparing UFH with LMWH (<a href="./references#CD003747-bbs2-0050" title="MismettiP , Laporte‐SimitsidisS , TardyB , CucheratM , BuchmullerA , Juillard‐DelsartD , et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low molecular weight heparins: a meta‐analysis of randomised clinical trials. Thrombosis and Hemostasis2000;83(1):14‐9. ">Mismetti 2000</a>). The meta‐analysis found a statistically significant decrease in DVT (RR 0.44; 95% CI 0.29 to 0.64; P &lt; 0.001) and clinical PE (RR 0.48; 95% CI 0.34 to 0.68; P &lt; 0.001) when heparin was compared to control, which are consistent with our review, although Mismeti identified a stronger relationship with PE as our findings for non‐fatal and fatal PE were imprecise and possibly due to chance effect. The Mismeti review found no difference in mortality, the same as our review, but they also found no difference in major bleeding, which is inconsistent with our review. No difference was observed in efficacy between UFH and LMWH in the Mismeti review, but our review found a decrease in DVT favouring LMWH. Also, our review found a decrease in major bleeding favouring LMWH, which is consistent with the Mismeti review findings. </p> <p>The Mismetti review used six of the same studies as we did for the comparison of heparin to control (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0002" title="BergmannJF , CaulinC . Heparin prophylaxis in bedridden patients. Lancet1996;348(9021):205‐6. MaheI , BergmannJF , d'AzemarP , VaissieJJ , CaulinC . Lack of effect of a low‐molecular‐weight heparin (nadroparin) on mortality in bedridden medical in‐patients: a prospective randomised double‐blind study. European Journal of Clinical Pharmacology2005;61(5‐6):347‐51. ">Bergmann 1996</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>; <a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>; <a href="./references#CD003747-bbs2-0011" title="Ibarra‐PerezC , Lau‐CortesE , Colmenero‐ZubiateS , Arévila‐CeballosN , FongJH , Sánchez‐MartínezR , et al. Prevalence and prevention of deep vein thrombosis of the lower extremities in high risk pulmonary patients. Angiology1988;39(6):505‐13. ">Ibarra‐Perez 1988</a>) and one study which was excluded from our review. For the comparison between UFH and LMWH, the Mismeti study analysed four studies used in our review (<a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>; <a href="./references#CD003747-bbs2-0007" title="ForetteB , WolmarkY . Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Presse Medicale1995;24(12):567‐71. ">Forette 1995</a>; <a href="./references#CD003747-bbs2-0015" title="KellerF , FlosbachCW , THE PRIME ‐ Study Group. A randomised multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Thrombosis and Haemostasis1995;73(6):1106‐Abstract No 788. LechlerE , SchrammW , FlosbachCW . A randomized, multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised patients. Annals of Hematology1994;68 Suppl 1:A55. LechlerE , SchrammW , FlosbachCW , The PRIME Study Group. The venous thrombotic risk in nonsurgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis1996;26 Suppl 2:49‐56. ">PRIME 1996</a>; <a href="./references#CD003747-bbs2-0016" title="KleberFX , WittC , VogelG , KoppenhagenK , SchomakerU , FlosbachCW , THE‐PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal2003;145(4):614‐21. ">THE‐PRINCE 2003</a>) and five studies that we excluded. While the authors described that they excluded cases of acute ischaemic stroke and acute myocardial infarction some of the studies included patients with acute coronary disease that could not be removed for analysis. Other criteria that warranted exclusion in our review were not upheld in the Mismeti review, such as detection method and inclusion of surgical patients, which led to differences in the profile of the included studies and the minor differences seen in the results. </p> <p><a href="./references#CD003747-bbs2-0038" title="DentaliF , DouketisJD , GianniM , LimW , CrowtherMA . Meta‐analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalised medical patients. Annals of Internal Medicine2007;146(4):278‐88. ">Dentali 2007</a> </p> <p>A meta‐analysis by Dentali et al assessed anticoagulant prophylaxis (UFH, LMWH and fondaparinux) to prevent symptomatic VTE in hospitalised medical patients (<a href="./references#CD003747-bbs2-0038" title="DentaliF , DouketisJD , GianniM , LimW , CrowtherMA . Meta‐analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalised medical patients. Annals of Internal Medicine2007;146(4):278‐88. ">Dentali 2007</a>). Nine trials were included in this analysis. Anticoagulant prophylaxis was associated with a borderline risk reduction in DVT (RR 0.47; 95% CI 0.22 to 1.00), which is consistent with this review. The Dentali review found a reduction in all PE (RR 0.43; 95% CI 0.26 to 0.71) for the prophylaxis group, but our review found no difference in non‐fatal and fatal PE. It was also noted in the Dentali review that anticoagulant prophylaxis was associated with a RR 1.32 (95% CI 0.73 to 2.37) for major bleeding, where our review found a statistically significant increase in major bleeding (OR 1.81; 95% CI 1.10 to 2.98; P = 0.02). </p> <p>The Dentali review considered seven of the same studies that we included in this review for the comparison between anticoagulant prophylaxis and control (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0002" title="BergmannJF , CaulinC . Heparin prophylaxis in bedridden patients. Lancet1996;348(9021):205‐6. MaheI , BergmannJF , d'AzemarP , VaissieJJ , CaulinC . Lack of effect of a low‐molecular‐weight heparin (nadroparin) on mortality in bedridden medical in‐patients: a prospective randomised double‐blind study. European Journal of Clinical Pharmacology2005;61(5‐6):347‐51. ">Bergmann 1996</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>; <a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>; <a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>) and two studies considered not relevant or excluded from our review. Although study inclusion and exclusion criteria were similar for the Dentali review and this review, the minor differences led to the different study profile and variations in results. A major difference is that the Dentali review included studies that observed effects of fondaparinux, and not solely heparin. Also, one included study did contain participants with a recent myocardial infarction, which excluded it from the current review. </p> <p><a href="./references#CD003747-bbs2-0032" title="BumpGM , DanduM , KaufmanSR , ShojaniaKG , FlandersSA . How complete is the evidence for thromboembolism prophylaxis in general medicine patients? A meta‐analysis of randomized controlled trials. Journal of Hospital Medicine2009;4(5):289‐97. ">Bump 2009</a> </p> <p>A meta‐analysis published in 2009 by Bump et al compared heparin prophylaxis to control in seven studies, and LMWH to UFH in six studies (<a href="./references#CD003747-bbs2-0032" title="BumpGM , DanduM , KaufmanSR , ShojaniaKG , FlandersSA . How complete is the evidence for thromboembolism prophylaxis in general medicine patients? A meta‐analysis of randomized controlled trials. Journal of Hospital Medicine2009;4(5):289‐97. ">Bump 2009</a>). Comparing heparin versus control, the authors found a decreased risk of all DVT, with a RR of 0.55 (95% CI 0.36 to 0.83), and all PE, with a RR of 0.70 (95% CI 0.53 to 0.93) in the heparin treatment group, but no difference in mortality between the groups (RR 0.92; 95% CI 0.82 to 1.03). The findings on all DVT and all‐cause mortality are consistent with our review, but our review found did not find a difference in non‐fatal and fatal PE. The Bump review did not find a difference between heparin and control for major bleeding, but in our review we found major bleeding to be significantly increased in the heparin group. For the studies comparing LMWH to UFH there were no statistically significant differences between the two treatment groups for DVT, PE, death or bleeding. The data on PE and death are consistent with our review, but we found a decrease in DVT and major bleeding favouring LMWH. </p> <p>For the comparison between heparin and control the Bump et al review included six of the same studies as in our review (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0002" title="BergmannJF , CaulinC . Heparin prophylaxis in bedridden patients. Lancet1996;348(9021):205‐6. MaheI , BergmannJF , d'AzemarP , VaissieJJ , CaulinC . Lack of effect of a low‐molecular‐weight heparin (nadroparin) on mortality in bedridden medical in‐patients: a prospective randomised double‐blind study. European Journal of Clinical Pharmacology2005;61(5‐6):347‐51. ">Bergmann 1996</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>; <a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>) with the addition of two studies that we excluded or considered not relevant. Comparing UFH to LMWH the Bump review included three of the same studies as in our review (<a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>; <a href="./references#CD003747-bbs2-0015" title="KellerF , FlosbachCW , THE PRIME ‐ Study Group. A randomised multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Thrombosis and Haemostasis1995;73(6):1106‐Abstract No 788. LechlerE , SchrammW , FlosbachCW . A randomized, multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised patients. Annals of Hematology1994;68 Suppl 1:A55. LechlerE , SchrammW , FlosbachCW , The PRIME Study Group. The venous thrombotic risk in nonsurgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis1996;26 Suppl 2:49‐56. ">PRIME 1996</a>; <a href="./references#CD003747-bbs2-0016" title="KleberFX , WittC , VogelG , KoppenhagenK , SchomakerU , FlosbachCW , THE‐PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal2003;145(4):614‐21. ">THE‐PRINCE 2003</a>) with two extra studies which were excluded from our review. Although the Bump review sought to exclude trials predominantly made up of stroke or acute myocardial infarction patients, it did include studies that had some of these types of participants that could not be separated out for statistical purposes. This difference, along with the review being conducted before some of the big trials included in our review were published, has lead to a different profile of included studies and variations in results. </p> <p><a href="./references#CD003747-bbs2-0048" title="LederleFA , ZyllaD , MacDonaldR , WiltTJ . Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: A background review for an American College of Physicians Clinical Practice Guideline. Annals of Internal Medicine2011;155(9):602‐15. ">Lederle 2011</a> </p> <p>A more recent meta‐analysis published by Lederle et al analysed 10 studies that compared prophylaxis with heparin or related agents to no heparin and nine studies comparing LMWH with UFH, all in hospitalised medical patients (<a href="./references#CD003747-bbs2-0048" title="LederleFA , ZyllaD , MacDonaldR , WiltTJ . Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: A background review for an American College of Physicians Clinical Practice Guideline. Annals of Internal Medicine2011;155(9):602‐15. ">Lederle 2011</a>). The review also analysed stroke patients, but this was performed separately and is not considered here. For studies that compared heparin prophylaxis with no heparin, a statistically significant decrease in PE was found in the heparin group with an OR of 0.69 (95% CI 0.52 to 0.90; P = 0.006), but our review found no difference in non‐fatal and fatal PE. In the Lederle review there were no differences found for symptomatic DVT, fatal PE or all‐cause mortality. The fatal PE and all‐cause mortality results are consistent with our review, but DVTs were found to be statistically decreased in the heparin group compared to the placebo or no treatment group. No difference in major bleeding was observed in the Lederle review (OR 1.49; 95% CI 0.91 to 2.43; P = 0.110), whereas in our review the increase in major bleeding in the heparin arm was statistically significant. No differences were found between LMWH and UFH for efficacy or safety outcomes, but in our review we found a statistically significant decrease in both DVT and major bleeding favouring LMWH. </p> <p>The Lederle review considered seven of the same studies as in the current review for the comparison between heparin and placebo or no treatment (<a href="./references#CD003747-bbs2-0001" title="BelchJJ , LoweGD , WardAG , ForbesCD , PrenticeCR . Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal1981;26(2):115‐7. BelchJJF , LoweGDO , WardAG , ForbesCD , PrenticeCRM . Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis1981;46(1):379‐Abstract No.1187. ">Belch 1981</a>; <a href="./references#CD003747-bbs2-0002" title="BergmannJF , CaulinC . Heparin prophylaxis in bedridden patients. Lancet1996;348(9021):205‐6. MaheI , BergmannJF , d'AzemarP , VaissieJJ , CaulinC . Lack of effect of a low‐molecular‐weight heparin (nadroparin) on mortality in bedridden medical in‐patients: a prospective randomised double‐blind study. European Journal of Clinical Pharmacology2005;61(5‐6):347‐51. ">Bergmann 1996</a>; <a href="./references#CD003747-bbs2-0005" title="DahanR , FauchetM , HoulbertD , CaulinC , SegrestaaJM . [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double‐blind clinical trial]. Therapie1986;41:522‐3. DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis1986;16(2):159‐64. DahanR , HoulbertD , CaulinD , SegrestaMM , et al. Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis1985;54(1):309‐Abstract No SS36. ">Dahan 1986</a>; <a href="./references#CD003747-bbs2-0008" title="FraisseF , HolzapfelL , CoulandJM , SimonneauG , BedockB , FeisselM , et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine2000;161(4 Pt1):1109‐14. ">Fraisse 2000</a>; <a href="./references#CD003747-bbs2-0010" title="Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low‐dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet1996;347:1357‐61. ">Gardlund 1996</a>; <a href="./references#CD003747-bbs2-0013" title="AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis2003;14(4):341‐6. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , EldorA , et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine2004;164(9):963‐8. AlikhanR , CohenAT , CombeS , SamamaMM , DesjardinsL , OlsonC‐G , et al. Benefit of enoxaparin in medical patients: A subgroup analysis. Blood2001;98(11):266A. AminAN , GirardF , SamamaMM . Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis2010;104(5):955‐61. CohenAT , ZawHM , AlikhanR . Benefits of deep‐vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology2001;38(2 Suppl 5):31‐8. SamamaMM , CohenAT , DarmonJY , DesjardinsL , EldorA , JanbonC , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine1999;341(11):793‐800. TurpieAG . Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology2000;86(12B):48M‐52M. ">MEDENOX 1999</a>; <a href="./references#CD003747-bbs2-0014" title="LeizoroviczA , CohenA , TurpieAGG , OlssonCG , VaitkusPT , GoldhaberSZ . A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract OC 396. LeizoroviczA , CohenAT , TurpieAG , OlssonC‐G , VaitkusPT , WeitzJI , et al. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood2003;102(11):Abstract 1153. LeizoroviczA , CohenAT , TurpieAG , OlssonCG , VaitkusPT , GoldhaberSZ , PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110(7):874‐9. VaitkusPT , LeizoroviczA , GoldhaberSZ , OlssonCG , CohenAT , WeitzJI , et al. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood2003;102(11):165a. VaitkusPT , LeizoroviczA , GoldhaberSZ , PREVENT Investigator Group. Rationale and design of a clinical trial of a low‐molecular‐weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine2002;7(4):269‐73. ">PREVENT 2004</a>), with the addition of three studies which were either considered not relevant or excluded from the current review. For the comparison between UFH and LMWH the Lederle review used five of the same studies as in our review (<a href="./references#CD003747-bbs2-0003" title="Anon . Efficacy and safety of low‐molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT003117532010. SchellongSM , HaasS , GreinacherA , SchwanebeckU , SiederC , AbletshauserC , et al. An open‐label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy2010;11(18):2953‐61. ">CERTAIN 2010</a>; <a href="./references#CD003747-bbs2-0004" title="Anon . A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT004514122007. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie2011;31(1):A5. BauersachsR , SchellongSM , HaasS , TebbeU , GerlachHE , AbletshauserC , et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis2011;105(6):981‐8. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , AbletshauserC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie2011;31(1):A10. HaasS , SchellongSM , TebbeU , GerlachH‐E , BauersachsR , MelzerN , et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer ‐ a subgroup analysis of CERTIFY. BMC Cancer2011;11:316. RiessH , HaasS , TebbeU , GerlachH , AbletshauserC , SiederC , et al. CERTIFY ‐ Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double‐blind, multicentre study. Onkologie2010;33(6):51‐2. RiessH , HaasS , TebbeU , GerlachH‐E , AbletshauserC , SiederC , et al. A randomized, double‐blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non‐surgical patients: the CERTIFY study. Hamostaseologie2010;30(1):A21. RiessH , HaasS , TebbeU , GerlachHE , AbletshauserC , SiederC , et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis2010;8(6):1209‐15. SchellongSM , GerlachH‐E , TebbeU , HaasS , AbletschauserC , SiederC , et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie2011;31(1):A87. SchellongSM , GerlachHE , TebbeU , HaasS , MelzerN , AbletshauserC , et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research2011;128(5):417‐21. TebbeU , SchellongSM , HaasS , GerlachHE , AbletshauserC , SiederC , et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal2011;161(2):322‐8. ">CERTIFY 2010</a>; <a href="./references#CD003747-bbs2-0006" title="BergmannJF , NeuhartE . A multicenter randomised double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis1996;76(4):529‐34. BergmannJF , for the Geriatric Enoxaparin Study Group, France . Prevention of venous thromboembolism in elderly medical in‐patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology1994;68 Suppl 1:A90. ">EMSG 1996</a>; <a href="./references#CD003747-bbs2-0015" title="KellerF , FlosbachCW , THE PRIME ‐ Study Group. A randomised multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Thrombosis and Haemostasis1995;73(6):1106‐Abstract No 788. LechlerE , SchrammW , FlosbachCW . A randomized, multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised patients. Annals of Hematology1994;68 Suppl 1:A55. LechlerE , SchrammW , FlosbachCW , The PRIME Study Group. The venous thrombotic risk in nonsurgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis1996;26 Suppl 2:49‐56. ">PRIME 1996</a>; <a href="./references#CD003747-bbs2-0016" title="KleberFX , WittC , VogelG , KoppenhagenK , SchomakerU , FlosbachCW , THE‐PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal2003;145(4):614‐21. ">THE‐PRINCE 2003</a>), with the addition of four studies that we either considered not relevant or excluded. The Lederle review extended inclusion to studies with common treatments for VTE, and not strictly heparin (which led to the inclusion of a study evaluating fondaparinux), and while studies including only acute myocardial infarction patients were excluded in the Lederle review it did include studies that had some acute coronary syndrome patients, which would have been excluded from our review. Also, the Lederle review was conducted before several newer studies were published that have been included in the current review. These differences can account for the variations in findings regarding both the heparin versus no heparin and UFH versus LMWH comparisons. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003747-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003747-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/full#CD003747-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003747-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD003747-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/full#CD003747-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003747-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD003747-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/full#CD003747-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003747-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Heparin versus placebo or no treatment, Outcome 1 Deep vein thrombosis." data-id="CD003747-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Heparin versus placebo or no treatment, Outcome 1 Deep vein thrombosis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#CD003747-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003747-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Heparin versus placebo or no treatment, Outcome 2 Non‐fatal pulmonary embolism." data-id="CD003747-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Heparin versus placebo or no treatment, Outcome 2 Non‐fatal pulmonary embolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#CD003747-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003747-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Heparin versus placebo or no treatment, Outcome 3 Fatal pulmonary embolism." data-id="CD003747-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Heparin versus placebo or no treatment, Outcome 3 Fatal pulmonary embolism.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#CD003747-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003747-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Heparin versus placebo or no treatment, Outcome 4 Combined non‐fatal and/or fatal pulmonary embolism." data-id="CD003747-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Heparin versus placebo or no treatment, Outcome 4 Combined non‐fatal and/or fatal pulmonary embolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#CD003747-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003747-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Heparin versus placebo or no treatment, Outcome 5 All cause mortality." data-id="CD003747-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Heparin versus placebo or no treatment, Outcome 5 All cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#CD003747-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003747-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Heparin versus placebo or no treatment, Outcome 6 Major bleeding." data-id="CD003747-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Heparin versus placebo or no treatment, Outcome 6 Major bleeding.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#CD003747-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003747-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Heparin versus placebo or no treatment, Outcome 7 Minor bleeding." data-id="CD003747-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Heparin versus placebo or no treatment, Outcome 7 Minor bleeding.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#CD003747-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003747-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Heparin versus placebo or no treatment, Outcome 8 Thrombocytopaenia." data-id="CD003747-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Heparin versus placebo or no treatment, Outcome 8 Thrombocytopaenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#CD003747-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003747-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Low molecular weight heparin versus unfractionated heparin, Outcome 1 Deep vein thrombosis." data-id="CD003747-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Low molecular weight heparin versus unfractionated heparin, Outcome 1 Deep vein thrombosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#CD003747-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003747-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Low molecular weight heparin versus unfractionated heparin, Outcome 2 Non‐fatal pulmonary embolism." data-id="CD003747-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Low molecular weight heparin versus unfractionated heparin, Outcome 2 Non‐fatal pulmonary embolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#CD003747-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003747-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Low molecular weight heparin versus unfractionated heparin, Outcome 3 Fatal pulmonary embolism." data-id="CD003747-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Low molecular weight heparin versus unfractionated heparin, Outcome 3 Fatal pulmonary embolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#CD003747-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003747-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Low molecular weight heparin versus unfractionated heparin, Outcome 4 Combined non‐fatal and/or fatal pulmonary embolism." data-id="CD003747-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Low molecular weight heparin versus unfractionated heparin, Outcome 4 Combined non‐fatal and/or fatal pulmonary embolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#CD003747-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003747-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Low molecular weight heparin versus unfractionated heparin, Outcome 5 All cause mortality." data-id="CD003747-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Low molecular weight heparin versus unfractionated heparin, Outcome 5 All cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#CD003747-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003747-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Low molecular weight heparin versus unfractionated heparin, Outcome 6 Major bleeding." data-id="CD003747-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Low molecular weight heparin versus unfractionated heparin, Outcome 6 Major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#CD003747-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003747-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Low molecular weight heparin versus unfractionated heparin, Outcome 7 Minor bleeding." data-id="CD003747-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Low molecular weight heparin versus unfractionated heparin, Outcome 7 Minor bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#CD003747-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003747-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/urn:x-wiley:14651858:media:CD003747:CD003747-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_t/tCD003747-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Low molecular weight heparin versus unfractionated heparin, Outcome 8 Thrombocytopaenia." data-id="CD003747-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Low molecular weight heparin versus unfractionated heparin, Outcome 8 Thrombocytopaenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#CD003747-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/media/CDSR/CD003747/image_n/nCD003747-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="comparison" data-id="CD003747-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Heparin versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.25, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Non‐fatal pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.20, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Fatal pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.43, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Combined non‐fatal and/or fatal pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27971</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.43, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.87, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.01, 2.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Minor bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [1.26, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Thrombocytopaenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.64, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Heparin versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#CD003747-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003747-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Low molecular weight heparin versus unfractionated heparin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.62, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Non‐fatal pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.42, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Fatal pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Combined non‐fatal and/or fatal pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.39, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.54, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.22, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Minor bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3876</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.48, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Thrombocytopaenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3876</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.08, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Low molecular weight heparin versus unfractionated heparin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003747.pub4/references#CD003747-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003747.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003747-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003747-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="ru#CD003747-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003747-note-0003">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003747\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003747\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003747\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003747\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003747\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003747\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003747\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003747\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003747\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003747\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003747\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003747\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003747\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003747\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003747\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003747\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003747\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003747\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003747.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003747.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003747.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003747.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003747.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714264329"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003747.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714264332"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003747.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6a717b80f3cd',t:'MTc0MDcxNDI2NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 